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Development of immunotoxins for clinical trials
P.E. Thorpe
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn
Fields, London WC2A 3PX, UK.
In many in vitro test systems, immunotoxins have been
shown to kill cancer cells with such outstanding potency and
specificity that we are encouraged to think they will provide
a new type of chemotherapeutic agent for the treatment of
human cancer. However, experiments in tumour-bearing
mice have revealed that immunotoxins are subject to a
number of problems in vivo which reduce their anti-tumour
activity. Three of these problems are: (1) ricin A-chain
immunotoxins are cleared rapidly from the bloodstream
because the oligosaccharides present on the toxin moiety are
recognised by the parenchymal and non-parenchymal cells of
the liver; (2) commercially available disulphide cross-linking
agents used to form A-chain immunotoxins give linkages
which are unstable in vivo; (3) free antibody is often present
as a contaminant in immunotoxin preparations and com-
petes for target antigens. The anti-tumour activity of ricin A-
chain immunotoxins is greatly improved by deglycosylating
the A-chain to prevent liver recognition, using a new, highly
stable cross-linker (SMPT) to form the immunotoxin, and
removing the contaminating free antibody by Blue Sepharose
chromatography. All but 0.001% of murine T-cell leukaemia
cells can be eradicated from tumour-bearing mice by a single
intravenous injection of immunotoxin. Immunotoxins of this
type can be used to treat patients suffering from B-cell
leukaemias and lymphomas.
Genetic basis of multidrug resistance
V. Ling
The Ontario Cancer Institute, Toronto, Canada.
Studies of multidrug-resistant (MDR) mutants have resulted
in new insights into anticancer drug transport in mammalian
cells. The simultaneous resistance to a wide variety of
unrelated compounds in MDR cells appears to be mediated
by an increase in a 170,000 daltons plasma membrane
glycoprotein (Pgp). Pgp appears to be encoded by a small
family of closely related genes. However, gene transfection
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studies indicate that transfer of a single member of the Pgp
genes is sufficient to mediate multidrug resistance. Analysis
of Pgp cDNAs revealed that Pgp has remarkable structural
homology to a number of bacterial transport proteins, and
that it has features (ATP-binding and pore-forming domains)
of a membrane pump protein. Thus it is envisioned that a
variety of compounds (including many anticancer drugs) are
exported from mammalian cells via this molecular pump
mechanism.
Despite this understanding of Pgp function, many basic
questions remain unanswered. These include: (1) what
mechanism(s) regulates Pgp expression? (2) what structural
features of Pgp are important for pump activity and for
recognising compounds that are exported? (3) is there a
normal substitute for Pgp, and what role does Pgp play in
normal cells? (4) what role is played by the different Pgp
gene members? (5) does the Pgp mechanism of drug resis-
tance play a role in the clinical response of patients to
chemotherapy?
In vitro and in vivo activities of a mouse-human chimaeric
B72.3 antibody
M. Bodmer, N. Whittle, J. Adair, C. Lloyd & J. Schlom
Department of Molecular Immunology, Celltech Ltd, Slough,
UK and NCI, NIH, USA.
B72.3 is a mouse IgGI antibody which recognises a tumour
associated antigen, TAG-72, found on a variety of human
carcinomas, including colon, breast and ovarian. Chimaeric
immunoglobulin genes with the B72.3 specificity have been
constructed by joining the mouse variable regions from
cDNA clones to human genomic gamma 4 and kappa
constant regions. The chimaeric immunoglobulin genes were
placed under the control of a strong viral promoter, and
transfected into COS-1 cells. SDS-PAGE analysis of the 35S-
labelled products demonstrated that the transiently expressed
antibodies were correctly synthesised, assembled and sec-
reted. The specific binding characteristics of the parent B72.3
antibody were retained by the chimaeric antibody in an
antigen-based ELISA. This system generated sufficiently high
transient expression of the chimaeric antibody molecules to
allow rapid physical and immunological characterisation of
the engineered gene products. Stable cell lines expressing
chimaeric antibody were made in CHO cells and purified
IgG has been used in quantitative studies. Competition
binding assays and tissue staining confirm the COS cell data
on activity and specificity. The localisation in vivo to LS174T
xenografts in nude mice is equivalent to the parent B72.3
antibody.
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Engineering antibody affinity and specificity
D.M. Webster, J.C. Cheetham, S. Roberts, R. Griest &
A.R. Rees
University of Oxford, Laboratory of Molecular Biophysics,
The Rex Richards Bldg, South Parks Road, Oxford OX]
3QU, UK.
In order to understand the way in which antibodies recog-
nise and bind to antigenic surfaces, detailed information
about the interactions between antibody and its epitope must
be defined. It is now possible to explore the molecular basis
of antibody affinity and specificity by combining the tech-
niques of molecular modelling using computer graphics,
energy calculations and protein engineering using site dir-
ected mutagenesis.
A panel of five monoclonal antibodies (mAb) (gloops 1-5)
are used in our laboratory to study antibody:protein antigen
interactions. These antibodies were raised against the iso-
lated 'loop' peptide, residues 57-83 of hen egg-white lyso-
zymes (HEWL) and selected by cross-reactivity with native
lysozyme. The antibodies are classified into three groups
which recognise dissimilar but overlapping epitopes. In addi-
tion we are examining antibody:DNA/RNA antigen inter-
actions with mAbs derived from systemic lupus
erythematosus prone mice.
Our studies have shown that we are able to specifically
engineer antibodies with altered affinities from the native
protein. The topographical surface of the anti-lysozyme
antibodies can be altered by a small number of changes,
resulting in effects on antibody binding, ranging from com-
plete abolition through to increased affinity for antigen.
From these studies we hope to establish the rules governing
antibody:antigen interactions and that an understanding of
such interactions will enable us to design antibodies of
clinical and industrial importance.
Structural analysis of high affinity monoclonal antibodies in
the secondary response
Deborah J. Allen, A. Cumano & K. Rajewski
Imperial Cancer Research Fund, Clare Hall Laboratories,
South Mimms, UK and Institut fur Genetik der Universitat
Zu Koln, Koln, W. Germany.
The primary immune response of C57B1/6 mice to the
hapten NP (4-hydroxy-3-nitrophenylacetyl) is characterised
by light chain-bearing antibodies of germline Vh gene
sequence. Upon secondary challenge with the hapten, anti-
bodies of increased affinity are observed which are exten-
sively mutated throughout their V regions. Amongst the
mutations observed, a tryptophan to leucine exchange
(TCG-TTG) at position 33 of the heavy chain is repeatedly
observed in independently isolated hybridomas. We have
used site-specific mutagenesis to introduce this single
exchange into a primary response antibody and show that
the hapten-binding affinity is increased by up to 10-fold. We
have also shown that restoring a tryptophan residue at
position 33 of a secondary response antibody (3B44) causes
a 10-fold decrease in affinity, implying that all other somatic
mutations in 3B44 were irrelevant to a selection of improved
hapten binding in vivo. However, in rare cases where the trp-
leu exchange is not observed in the secondary response, we
have shown, by recombinant antibody construction, that
structures in the third complementary-determining region
may influence selection of other mutations in the VH region
which lead to increased affinity.
Therapy with hybrid antibodies
M. Clark & H. Waldmann
Division of Immunology, Department of Pathology,
University of Cambridge, Tennis Court Road, Cambridge
CB2 IQP, UK.
The cell fusion of two Ig producing cell lines results in the
codominant expression of all of the parental cell derived Ig
chains. For a cell making two Ig heavy chains and two Ig
light chains a random association of all chains results in ten
possible configurations of secreted antibody species. The
interest in these antibodies for therapy stems from the
biological properties of different species within the complex
mixture. In addition to the properties which depend upon
the interaction of different Ig isotypes with human effector
mechanisms there are unique properties which result from
the different binding specificities for antigen. For example,
certain species of antibody are monovalent for binding to a
given antigen. Such monovalent antibodies with specificities
for modulating cell surface antigens seem to be more
efficient than the equivalent bivalent antibodies at lysing
target cells with complement. Monovalent CD3 antibody is
currently being used therapeutically. Another of the compo-
nents of the mixture has dual specificity for the two different
antigens recognised by the parental antibody types. These bi-
specific antibodies are capable of targeting drugs or toxins to
cells expressing appropriate cell surface antigens. Also of
interest is the ability of these bi-specific antibodies to induce
very potent tumour cell killing by activated T-cell blasts
when the bi-specific antibody is used to cross-link a compo-
nent of the T-cell receptor complex and a suitable cell
surface antigen on the target cell.
Radioimmunoimaging - a critical review
G.L. DeNardo, S.J. DeNardo, D.J. Macey, C.F. Meares &
S.V. Deshpande
University of California, Davis Medical Center, Sacramento,
CA, USA.
Calculations based upon cell and antigen densities and
scintillation camera sensitivities suggest that radioimmuno-
imaging (RII) has the potential in theory to detect cancers
smaller than currently possible by existing imaging tech-
niques and prior to likelihood of metastasis. While clinical
trials of RII have not been extensive thus far, they have
provided results far short of that theoretically possible.
Detection of 60-90% of lesions and lesions not detectable by
other methods has been reported for several different
antibody-radionuclide systems, but lesions with diameters
less than 1-2cm have often been missed. Many factors
degrade the imaging potential of RII. Some of these are
amenable to solution through improved radionuclides, radio-
chemistry, antibodies and so forth. More challenging
obstacles relate to delivery of the radionuclide to the
tumour. Creativity has already led to several proposals for
enhanced delivery. These include the use of radiation, bio-
logical response modifiers, antibody fragments and hybrid
antibodies. It seems wiser at this stage of development to ask
the right questions rather than make predictions for the
future. The following are among the more interesting
questions: can the difference between tumour and tissue
vessels be used to enhance tumour uptake; why do some
patients develop HAMA; why are some antibodies recog-
nised as different in the species of origin as well as other
species; do affinity and avidity influence tumour uptake in
vivo?MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 305
Dosimetry and suppression of the human antimouse response
in iodine-131 labelled antibody therapy of cancer
R.H.J. Begent
Cancer Research Campaign Laboratories, Department of
Medical Oncology, Charing Cross Hospital, Fulham Palace
Road, London W6, UK.
The techniques of molecular biology and modern immu-
nology give us many molecules which have potential for
targeting to cancer. Only quantitative clinical study can
identify those which will be of value to patients. Methods for
quantitative clinical testing are now being developed with
radiolabelled antibodies. Three-dimensional (SPET) gamma-
camera imaging is necessary for accurate radiation dose
measurements and these must be done from the day of
administration for 2-3 weeks. Means of avoiding the inac-
curacies inherent in the method have been developed. With
this system great variation in the efficiency in antibody
localisation has been shown and some prediction of response
is possible in patients with colorectal cancer treated with
iodine13 3-labelled antibody to CEA. It is also evident that
the best therapeutic ratio (11:1) occurs after the first two
days, especially if second antibody is given. This favours the
use of dual phase system for targeted therapy. Even so it is
likely that multiple dose therapy will be needed and preven-
tion of the human antimouse response will be necessary. We
have shown that cyclosporin A can delay and reduce the
intensity of human antimouse antibody production so that
up to four times as many doses of antibody therapy can be
given in man. This ability to give repeated therapy and to
measure the efficiency of targeting provides the means to
select patients for effective anti-tumour therapy.
The use of antibodies to study oncogenes, growth factors
and their receptors
W.J. Gullick
ICRF Oncology Group, Royal Postgraduate Medical School,
Hammersmith Hospital, London, UK.
One of the features that distinguishes tumour cells from
normal cells is the ability of the former to grow rapidly in
low concentrations of serum. Investigations of this obser-
vation at the molecular level have revealed that molecules
normally involved in growth control are frequently aber-
rantly expressed by tumour cells. Many of the genes encod-
ing such molecules can be activated by mutation to forms
capable of transforming cells. These genes, termed onco-
genes, encode growth factors, growth factor receptors and
molecules in the cytoplasm and cell nucleus involved in
transduction of growth regulatory signals.
We have investigated the production of growth factors
and their receptors in a variety of primary human tumour
biopsies. The epidermal growth factor receptors and the
structurally related c-erbB-2 protein have been found to be
frequently over-expressed in a variety of human carcinomas
as assessed by immunohistological staining and Western
blotting. The number of gene copies of both these molecules
are also often increased in tumours.
We have examined the role of these changes in the
instigation and maintenance of the transformed phenotype as
well as their value in prediction of tumour behaviour.
Structure and epitope mapping of an immunogenic region of
a human polymorphic epithelial mucin
Advances in immunohistology
Eadie Heyderman & A.M.R. Haines
Department of Histopathology, UMDS, St Thomas'
Hospital, London SE] 7EH, UK.
The majority of histopathological diagnoses are made on the
basis of routine H&E preparations, supplemented by special
histological techniques such as PAS, reticulin, and Masson-
Fontana stains. In the primary care hospital about 3-10% of
cases require further immunohistochemical investigations for
diagnosis, and/or more precise classification, as for example
in lymphomas. There are problems associated with the
interpretation of immunohistology, since the technique can
only demonstrate stored antigen, and cannot distinguish
between synthesised and phagocytosed material. Cells which
export their product rapidly may appear negative. Notwith-
standing these problems, which may be approached by in
situ hybridisation of mRNA, useful additional information
may be obtained. With the advent of more effective and
potentially toxic therapy, definitive diagnosis has become
even more important. In addition the possibility of antibody-
directed therapy, using conjugates of specific antibodies and
various toxins, requires mapping of the distribution of the
appropriate antigen, to avoid damage to normal tissues
expressing the same epitope as the tumour. The most specific
epithelial markers presently available include those directed
against prostatic acid phosphatase and against thyroglobulin,
although the epitopes recognised by these have been loca-
lised on occasional non-prostatic and non-thyroid tissues.
Taken together with the H&E morphology other less speci-
fic markers may still give important diagnostic information.
Joyce Taylor-Papadimitriou, Sandra Gendler, Joy Burchell,
J. Rothbard & T. Duhig
Imperial Cancer Research Fund, Lincoln's Inn Fields,
London, UK.
The human epithelial mucins are very immunogenic in the
rodent, with the result that many antibodies selected for
epithelial or carcinoma specificity are directed to these
components. It is not yet clear how many genes there are
which code for the different mucines, and whether more than
one of these genes is expressed by a single cell type. Recently
however we have obtained partial cDNA clones for the
human mammary mucin which have allowed us to predict
the sequence for part of the core protein of this mucin and
to look for its expression in a variety of cell types. The gene
shows a polymorphism which is due to the presence of
varying numbers of a 60bp tandem repeat element. Southern
blots of restriction enzyme digests show that only one gene
with this structure is present in the human genome (two
alleles) indicating that other mucin genes do not show a
strong homology, at least in this region. The mucin probe
cross-reacts with digests of primate DNA, but not with
rodent, thus explaining the immunogenicity of the mammary
mucin in mice. A synthetic peptide corresponding to the a.a.
sequence predicted from one open reading frame of the
tandem repeat reacts with antibodies HMFG-1, HMFG-2
and SM-3, each of which binds to a different epitope. The
identification of epitopes which are preferentially expressed
on carcinomas should allow (1) a directed approach to the
production of more tumour specific antibodies and (2) a
study of the differences in the processing of the mucin seen
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Uptake of radiolabel in rat liver cells after administration of
radiolabelled B72.3 and its F(AB')2 fragments
H. Sands, P.L. Jones, B.A. Brown & T. Nason
Medical Products Department, E.L. duPont & Co., N.
Billerica, MA, USA.
We have previously reported that in rats injected with intact
murine anti-human tumour antibody, B72.3, labelled with
either 12 I(I) or I 1ln(In), the liver uptake of radiolabel is
predominantly due to accumulation by the liver parenchymal
cells. To determine the effect of removal of the Fc portion
on liver cell uptake we have measured the uptake of
radiolabel by rat liver cells of animals injected i.v. with either
intact B72.3 and its F(ab')2 labelled with either I or In. One
hour after administration, liver cells, obtained by collagenase
perfusion, were separated into parenchymal (PC) and non-
parenchymal (NPC) fractions using Percoll gradients. 77.9%
and 80.8% of the label recovered was PC-associated when I-
or In-labelled B72.3 was administered, while after I- and In-
F(ab'2) administration, 96% and 94.6% of the label was
recovered in the PC fractions. The absolute uptake of In-
F(ab')2 was similar to that of I-F(ab')2 but was 54% of that
seen with the IgG. To determine whether the lower absolute
liver uptake of F(ab')2 was due to the absence of Fc binding
or was a result of more rapid blood clearance, the uptake of
B72.3 and its F(ab')2 labelled with I or In was measured in
the perfused rat liver. When compared with data obtained
from livers of rats injected with labelled antibodies, the
uptake of I- and In-B72.3 in the perfused liver was reduced
by 57.2% and 92.3%, respectively, by removal of Fc. Thus
Fc binding is a major component contributing to liver
uptake of IgG. When the liver uptake of B72.3 and its
F(ab')2 labelled with 99Tcm using rabbit metallothionein as
the radionuclide chelator was studied, >84% of recovered
99Tcm was in the PC fraction. In summary, PC are the major
liver cell of radionuclide accretion regardless of either the
specific radionuclide or whether the label is attached to IgG
or F(ab')2.
Immunogold and immunogold/silver in the ultrastructural
localisation of target molecules identified by monoclonal
antibodies
Rosemonde Mandeville & M.G. Zelecowska
Immunological Research Center, Institut Armand-Frappier,
Laval-des-Rapides, Quebec, Canada H7N 4Z3.
The use of colloidal gold and colloidal gold followed by
silver enhancement are two highly sensitive and accurate
techniques for the visualisation of target molecules identified
by monoclonal antibodies (MAbs). Gold probes were par-
ticularly useful when used at two different particle sizes (5
and 20nm in diameter) in a double labelling method for the
identification of two antigens on the same grid. We have
also combined gold and gold/silver staining in a double
staining technique for the simultaneous localization of breast
cancer-associated antigens using BCD-E8 and BCD-F9
Mabs. These techniques have also been used to demonstrate
the internalisation of the gold-labelled BCD-F9 MAb in
MCF-7 cells by warming for 30min at 37°C. We conclude
that colloidal gold and gold/silver markers constitute valu-
able and versatile tools for the ultrastructural localisation
and quantitation of target molecules identified by MAbs and
that further development of these techniques may have an
important impact on the development and use of MAbs in
oncology.
The presence of multiple tumour-associated epitopes on an
immunopurified antigen and its use to generate further
monoclonal antibodies
A.B. Griffiths & Joyce Taylor-Papadimitriou
Imperial Cancer Research Fund, London, UK.
The monoclonal antibody HMFG2 is well characterised and
recognises a determinant on high molecular weight glyco-
proteins present in epithelial cells and associated with malig-
nancy, notably ovary and breast. In comparative
immunoblots we have shown that many antibodies raised
and selected for their reactivity with carcinomas also react
with glycoproteins similar to those recognised by HMFG2.
We have immunopurified material bearing the HMFG2
component on an HMFG2 affinity column from membrane
preparations of the breast cell lines T47D and MCF7 and
demonstrated the cross-reactivity of this immunopurified
material with other antibodies in a solid phase ELISA assay.
This confirms that this material bears many tumour asso-
ciated determinants, defined by monoclonal antibodies, and
may be important in the study of the malignant phenotype.
Western blots and silver staining of the PAGE separated
immunopurified material demonstrate the presence of the
high molecular weight components. This material has been
used to generate further monoclonal antibodies. These
include two antibodies which, on Western blots of PAGE
separated T47D and MCF7 cells, recognise, in addition to
the high molecular weight material, a band at 68 K identical
to that seen in the immunopurified material used as antigen.
This suggests that the 68 K material recognised by these
antibodies may share a function as well as immunological
relationship with the high molecular weight material on
which many cancer related determinants are expressed. Other
antibodies produced recognised a large proportion of breast
cancers and may be useful for immunolocalisation.
Enzyme immunoassay detection of ovarian cancer-associated
sebaceous gland antigen (SGA) on biological fluids
G.T. Layton, M.J. Baily, P.L. Devine, G.W. Birrel &
J. Golder
Medical Innovations Ltd., 11 Technology Drive, Labrador,
Queensland 4215, Australia.
The monoclonal IgM antibody OM-1 has previously been
shown by immunohistology to react with primary and
metastatic ovarian serous cystadenocarcinomas, endometroid
carcinomas and with ovarian tumour cell lines. The antigen
was also found in sebaceous glands in normal skin and was,
thereore, termed sebaceous gland antigen (SGA). In order to
investigate the presence, distribution and possible signifi-
cance of SGA molecules in serum and other biological fluids
we have developed and sandwich enzyme immunoassay.
OM-1 was purified from ascites and an aliquot was biotiny-
lated. The assay procedure involves firstly coating microtitre
plate wells with OM-l antibody. Then the test samples, OM-
1 biotin, streptavidin-horseradish peroxidase conjugate and
finally substrate are sequentially incubated in the coated
wells, with washes between each stage to remove unbound
material. Using this method, SGA was detected in the
culture supernatants of ovarian tumour cell lines and in sera
and ascites from patients with ovarian cancer. SGA could
also be detected in a human milk fat globule membrane
preparation. A semi-quantitative assay has now been estab-
lished to evaluate the diagnostic and therapeutic monitoring
potential of SGA measurement in ovarian cancer.MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 307
Preoperative discrimination between benign and malignant
ovarian tumours using a combination of CA125 and CA15.3
serum assays
C. Yedema, L. Massuger, J. Hilgers, L. Poels,
C. Schijf, R. Verheijen, C. Thomas & P. Kenemans
Department Ob/Gyn, Radboud Hospital, Nijmegen and
Department Ob/Gyn, Free University Hospital, Amsterdam,
The Netherlands.
Most ovarian cancer patients have elevated CA125 levels in
pretreatment serum. A number of patients with benign
ovarian neoplasms, are also found to have elevated CA125
serum levels. Therefore, if CA125 levels are measured alone,
an overlap between both groups is observed. The present
study was initiated to achieve a better discrimination
between both groups mentioned, using a combination of two
tumour marker serum assays CA125 and CA15.3. In pre-
operative sera of 38 well staged ovarian cancer patients and
32 patients with benign ovarian neoplasms both CA125 and
CA125 (>35Uml-1) were observed in 71% and elevation of
CA15.3 (>3OUml-1) in 50%. Within the group of patients
with benign ovarian neoplasms, elevation of CA125 and
CA15.3 was observed in 25% and 9% respectively. Of these
ovarian cancer patients with normal CA125 serum levels, 10
out of 11 had stage I disease and a borderline or a mucinous
carcinoma. In the entire group of 70 patients, CA125 serum
levels were elevated in 35 patients, of which 27 had ovarian
cancer and 8 a benign ovarian tumour. Out of 8 patients
with false positive CAl25 elevation only one had an elevated
CAl5.3 level, whereas in 27 correct positive patients 19 had
elevated CAl 5.3 levels.
In cases of simultaneous elevation of both tumour markers
(20 patients) 95% had ovarian cancer. If for CA125 a cut-off
level of 65Uml-1 was used, all patients with both tumour
markers elevated (19 patients) were found to have an
ovarian malignancy. Determination of a panel of tumour
markers seem to be useful in the preoperative screening of
ovarian tumours.
Some aspects of antibody labelling with metallic
radionuclides
H. Maecke, T. Kaden, A. Riesen, W. Ritter & M. Studer
University Hospital Basel, Departments of Nuclear Medicine
and Chemistry, University of Basel, Switzerland.
Bifunctional ligands with the ability to bind metallic radio-
nuclides and to be covalently linked to biomolecules are of
interest due to the need of versatile methods for the labelling
of antibodies. We synthesised functionalised macrocycles and
examined their suitability in the labelling of antibodies with
64Cu, 57Co (55Co), 11'In and 90Y. Monofunctionalised
macrocycles proved to be appropriate for Cu2+ aksd
Co2+(Co3+). The complexes are extremely stable and no loss
of cobalt or copper was found even in acidic solutions for
days.
Moreover new ligands were synthesised designed to com-
plex I In3 + and 9OY3+. Convenient starting materials to
bifunctional ligands 1,4,8,1 1-tetraazacyclotetradecane-
N,N'N"-triacetic acid (14-aneN4triac) were synthesised.
Alkylation at the secondary amine results in bifunctional
compounds. We studied aspects of basic In3'-coordination
chemistry in relation to antibody labelling as well as kinetic
and thermodynamic data. Some of the complexes were fully
characterised by X-ray crystallography. Interestingly In(14-
aneN4.4H20) complex is octa-co-ordinate. The dtpa-ligand
binds through the three bitrogen donors and five deproto-
nated carboxylate groups.
A new monoclonal antibody (MOvl8) against ovarian cancer
for imaging and therapy
F. Crippa, M. Gasparini, E. Seregni, S. Canevari,
M. Ripamonti, F. Landoni, R.V. Fontanelli,
G.A. Scassellati & G.L. Buraggi
National Cancer Institute, Milan, Ospedale S. Gerardo,
Monza and Sorin Biomedica, Italy.
A new monoclonal antibody (MOv18) against human ovar-
ian cancer was labelled with 1311 using the iodogen method
and prepared for human administration by Sorin Biomedica,
Saluggia. Clinical trials with radiolabelled MOvl8 are in
progress to evaluate its possible applications in tumour
detection and therapy. At present, 20 patients with advanced
ovarian carcinomas received intravenous or intraperitoneal
MOvl8 antibody (mean activity injected 86.81 MBq, mean
quantity of monoclonal antibody 0.425mg), and its biodistri-
bution and tumour localisation were evaluated by sequential
immunoscintigraphy during weeks 1-2 after administration.
All the patients were subjected to a surgical second look
after immunoscintigraphy. Our preliminary results demon-
strated that MOv18 is a suitable reagent for in vivo
(immunoscintigraphy of ovarian carcinoma and potential
radioimmunotherapy.
Successful imaging of metastatic tumours using labelled
monoclonal antibodies: A prelude to therapy
P.G. Abrams, R.W. Schroff, M.F. Fer, D. Salk,
D.S. Wilbur, J. Sinkule, J.F. Eary & W.B. Nelp
NeoRx Corporation and the Division of Nuclear Medicine,
University of Washington, Seattle, USA.
Therapeutic applications of monoclonal antibodies are
dependent at least on their targetting to tumours without
significant concurrent localisation in normal organs. Thus,
successful imaging strategies serve as a safe, rapidly deve-
loped prelude to therapy. To date, nearly 200 patients with
melanoma, lung and colon cancer have been successfully
imaged using Fab fragments of NR-Ml-05, NR-Lu-10 and
NR-Ce-01 antibodies all linked to 99Tcm by a stable chelat-
ing system. Toxicity, allergic in nature, was rare (1.5%),
readily reversible and never prevented completion of the
study. Images were obtained in 6-20h. Previously known
and occult metastases were detected in liver, bone, skin,
brain, lymph node, adrenal, ovary, spleen and lung, the
latter having a lower detection rate for reasons as yet
unexplained. Accumulation of the labelled antibody was
observed in thyroid (cross-reactivity) and occasionally in
areas of osteoarthritis positive on bone scan, and infre-
quently in inflammatory lesions. Excretion of the label via
the renal and hepatobiliary routes complicated image inter-
pretation. Results of imaging assisted in patient manage-
ment. We conclude that 99Tcm may be stably chelated to
antibody fragments. The resulting immunoconjugates
provide useful staging information in a single diagnostic
scan. Elimination of hepatobiliary excretion will improve
image interpretation. We have also shown that stable iodine
and rhenium chelated antibodies, as well as doxorubicin,
trichothecene conjugates, can target tumours in nude mice
equal to antibody alone.308 MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY
The use of macrocyclic ligands in radioimmunoconjugates
M.A.W. Eaton, D. Parker & A. Harrison
Celltech Group, plc, Department of Chemistry, University
of Durham and MRC Radiobiology Unit, UK.
The essence of effective and efficient radioimmunodiagnosis
and therapy is to ensure that the radionuclide remains
attached to the antibody in vivo. None of the commonly
used acyclic chelates (EDTA, DTPA-based) are really
adequate for binding metallic isotopes because of the facility
of metal dissociation. Such problems may be obviated with
macrocyclic ligands (provided that they are judiciously
designed) because acid-promoted dissociation is much
slower. New methods have been developed for the selective
attachment of these macrocycles to thiol residues on an
antibody. Conditions for radiolabelling the macrocycle-
antibody conjugate have been established, and animal data
for 99Tcm and 64Cu labelled antibody are encouraging. These
results have clinical implications and could lead to improved
protocols for 186Re and 67Cu radioimmunotherapy.
Polyazamacrocyclic chelating agents for radioimmunoimaging
and radioimmunotherapy
O.A. Gansow, M.W. Brechbiel, K. Kumar, S. Mirzadeh,
T. McMurry & M. Magerstadt
National Institutes of Health, Bethesda, MD 20892, USA.
Polyazamacrocyclic polymethylenecarboxylate chelating
agents exhibit the highest thermodynamic stability constants
known for the radionuclides 90Y, 203Pb, 212Bi of potential
use in imaging and radioimmunotherapy. Yet no studies of
the DOTA complexes with these isotopes or of the synthesis
of a bifunctional DOTA have been published.
We report that complexes of the above named radio-
nuclides with DOTA have been synthesised and their kinetics
of isotope exchange and dissociated in aqueous media exa-
mined. All complexes are kinetically inert from pH 3 to 9.
In view of the likely importance of 212Pb as a carrier of
alpha emitter 212Bi for radioimmunotherapy, we have care-
fully examined the retention of the 212Bi in DOTA when
produced by radiodecay of the parent 212Pb and are able to
report substantial retention of the daughter radionuclide.
Syntheses for 1-(p-isothiocyanatobenzyl)DOTA have been
achieved.
Tumour localisation studies with streptavidin and biotin
D.J. Hnatowich, G. Rowlinson, M. Rusckowski, D. Snook
& A.A. Epenetos
University of Massachusetts, USA and Hammersmith
Hospital, London, UK.
Using a human tumour xenograft model, we are investi-
gating the use of streptavidin-conjugated anti-tumour anti-
body HMFG1 (S-GI) administered prior to the
administration of radiolabelled biotin as a means of improv-
ing tumour targeting. Nude mice implanted subcutaneously
with HEP-2 tumour, were administered i.v. with 9g S-G1
and, at 1, 4 and 7 days thereafter, were administered with
11In-biotin. Biodistribution was compared with that
obtained in the conventional manner with 11In-HMFG1.
Animals were killed and dissected 2h after administration of
biotin at either 0.1, 1, 10 or 100pg per animal. Radioactivity
levels in normal tissues were substantially reduced at all time
points with respect to the conventional labelling procedure.
These levels were also reduced in tumour, the tumour to
normal tissue ratios (with the exception of kidneys) were
improved up to four-fold.
These studies demonstrate the potential of this approach
for tumour imaging, at earlier times after administration
than with the conventionally labelled antibody.
In vivo tumour localisation by means of biotinylated
monoclonal antibodies and radioactive streptavidin: a novel
approach to cancer targeting
G. Paganelli, G. Rowlinson, S. Pervez, G. Deleide,
F. Chiolenio, M. Malcovati, A.G. Siccardi & A.A. Epenetos
M. Buffalini Hospital, Cesena, Italy and Hammersmith
Hospital, London, UK.
Nude mice bearing intraperitoneal human colon carcinoma
tumours were injected with biotinylated monoclonal anti-
body AUA1, followed 24h later by radioiodinated strepta-
vidin as a control study. A direct method of peroxidase
staining using peroxidase-conjugated streptavidin showed the
in vivo presence and distribution on tumour of biotinylated
MoAbs. Autoradiography was also performed as a compari-
son study to demonstrate targeting of radioactive streptavi-
din to biotinylated antibody. Our results show that this two-
step approach: (1) increased the percentage of radioactivity
uptake by tumour (24% vs. 6%); (2) improved the target to
non-target ratio (improvement index greater than 6.5); (3)
has advantages over a single step approach using radio-
labelled antibody in vivo.
Sensitivity, toxicity and immunogenicity of human
monoclonal antibodies in imaging patients with colon cancer
R.P. McCabe, R.G. Steis, J.A. Carrasquillo, J.C. Reynolds,
M.V. Haspel, E.M. Paris, M.M. Kopciensky &
M.G. Hanna, Jnr.
Organon Teknika Corporation, Bionetics Research Institute,
NCI and NIH, USA.
Positive tumour images were obtained in 20 out of 24
patients with colon cancer receiving 131I-labelled human
monoclonal antibodies 16-88 or 28A32. Lesions as small as
1.5cm were detected. Limited antibody related toxicity (urti-
caria) was seen in two patients. This was not dose related.
No evidence of toxicity was seen with 16-88. Sera were tested
for anti-antibody activity up to four weeks after receiving up
to 200mg human monoclonal antibody for four consecutive
weeks. No anti-16-88 activity was seen in any patient. Anti-
28A32 activity was seen in pre-treatment sera from two
patients with positive skin tests who did not enter the study,
from the two patients who developed urticarial rashes after
infusion of 28A32 and from one of two patients whose
tumour was not detected by 1311-28A32. Those patients who
received 28A32 infusion exhibited only a four-fold increase
in anti-28A32 titre over the 2-month observation period. At
present it is not known whether the pre-existing anti-
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evidence suggests that pre-existing antibody to 28A32 may
be a selection factor in identifying the most appropriate
human monoclonal antibody for use in patients, and that a
panel of human monoclonal antibodies is needed to provide
the most appropriate antibody for the greatest number of
patients.
Comparison of the specificity of monoclonal antibodies to
malignant gliomas
B.A. Watkins, Pat Carter, F. Scaravilli, L.W. Duchen &
D.G.T. Thomas
Institute of Neurology, Queen Square, London WCIN 3BG,
UK.
Recent developments in the differential diagnosis of the
small cell cancers of childhood have centered on the use of
monoclonal antibodies to identify cell-type specific antigens
in specific types of neoplasm. In addition, radiolabelled
monoclonal antibodies have proven useful in tumour imag-
ing and in the treatment of diffuse neoplastic meningitis.
In an attempt to extend the use of monoclonal antibodies
into differential glioma diagnosis, antibodies were raised
against three malignant gliomas, using standard techniques.
A total of 281 hybridoma clones were raised and tested for
reactivity against the glioma used for the initial immunisa-
tion. Six antibodies were selected for further study on the
basis of their strong anti-glioma reactivity with non-
neoplastic brain tissue.
These antibodies were tested against a large panel of glial
and non-glial brain tumours, and each showed a highly
characteristic staining pattern. Th]ie patterns of reactivity seen
in sections stained with these antibodies suggest that each
antibody stains specific groups of cells within glial tumours.
The specificity shown by these antibodies for glioma tissue
as opposed to normal brain, and their apparent specificity
for particular sub-sets of glioma cells suggest that these
antibodies may prove useful in the diagnosis, imaging and
therapy of malignant gliomas.
Radioimmunoscintigraphy of high-grade brain gliomas
D.V. Skarlos, J. Malamitisi, G. Augustatos,
N. Demakopoulos, A. Varvarigou, T. Giannakakis,
P. Economidis, C. Kotoulidis & A. Epenetos
3rd Med. Onc. Department of Ag. Anargiri Cancer
Hospital, Nucl. Department of NIMTS Hospital, Athens and
ICRF Onc. Group, Greece.
Ten patients with relapsed gliomas grade III, IV and a
patient with astrocytoma grade I were studied with 1311_
H17E2. Additionally, two patients with glioma III, IV were
studied with a non-specific anti-idiotype 2118 MCA. 1.5-
2.0mCi (55-74MBq) were administered intracarotically (i.c.)
or intravenously (i.v.). Immunoscans were taken at 0, 2, 24,
48 and 72 h and kinetics of the MCAs were studied. See
table.
131I-H17E2 produced positive scans with gliomas grade
III, IV but not with astrocytomas. These findings correlate
with immunohistochemical data. Intravenous route of admi-





no. CT of adm 48h 72h 48h 72h
1 + IC + + 2.25 2.34
2 + IC + + 1.43 1.42
3 + IV + + 1.79 1.87
4 + IV + + 2.20 2.45
5 + IV + + 1.49 2.21
6 + IV + + 1.37 1.41
7 + IV + + 1.50 1.72
8 + IV n.t. + n.t. 1.74
9 + IV - + 1.19 1.25
10 + IV - - 1.10 1.07
11 + IV + + 1.87 1.89
12 + IV + - 1.23 1.09
13 + IV - - 1.04 1.09
Patient 10 had astrocytoma grade I. Patient 11 received non-
specific MCA three weeks after administration of H17E2. Patient 13
received only non-specific MCA.
n.t. =not taken.
Scintigraphic tumour imaging with biotin-conjugated
antibodies and radiolabelled streptavidin
P. Oehr, J. Westermann, U. Germer, A. Bockish &
H.J. Biersack
Institute of Nuclear Medicine, University of Bonn, FRG.
We used nude rats bearing cytokeratin-positive solid HeLa
cell carcinomas on their hind leg. The binding of monoclonal
anti-cytokeratin antibodies to the tumour was demonstrated
in vitro by immunohistochemical staining and in vivo by
means of radioimmunodetection with 125I-labelled anti-
bodies. The animals were preinjected i.v. with 'cold' biotin-
conjugated anti-cytokeratin antibodies. At a later time 1251_
labelled streptavidin was administered i.v. In another
approach the animals received an additional injection with a
specific anti-antibody to the previously administered anti-
cytokeratin antibody in order to reduce free antibodies in the
circulation. In the streptavidin-biotin system the tumour
could be localised within 60min, whereas it took at least
three days with the directly labelled antibody. Using the
anti-antibody the tumour could be seen 15min after injec-
tion. A limitation of the system was some antibody-
independent binding of streptavidin to the tumour as well as
to other organs, especially kidney and liver.
Immunoscintigraphy in breast cancer with 123I-labelled
monoclonal antibodies (MOAbs)
S.E.M. Clarke, C. Twelves, C. Lazarus, A. Girling,
S. Allen, S. Mather, J. Taylor-Papadimitriou & I. Fentiman
Department of Nuclear Medicine, ICRF Breast Unit, Guy's
Hospital and ICRF, Lincoln's Inn Fields, London WC2, UK.
The presence of tumour involved nodes in patients with
breast cancer can at present only be demonstrated following
surgical resection. We have assessed the uptake of two 1231-
labelled MoAbs, HMFG1 and SM3 in patients undergoing
mastectomy with axillary clearance. Fourteen patients have
been studied, 4 with HMFG1 injected subcutaneously (s.c.)
into the finger webs of both hands, 4 with SM3 injected s.c.,
and 6 with SM3 injected intravenously (i.v.).
Patients were imaged at 1, 4 and 20h after injection and
blood and urine samples were collected. The resected speci-
men was imaged, the nodes and tumour then dissected,
counted individually and examined histologically.310 MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY
Imaging showed symmetrical uptake in both axillae
following subcutaneous injection, and no tumour uptake was
observed after IV injection of SM3. Determination of
amount of antibody in modes and tumour showed no
significant uptake in tumour or tumour bearing nodes
following s.c. or i.v. administration of either antibody. The
following table shows the mean percentage injected 1231
MoAb/g of tissue.
Normal Tumour
nodes nodes Tumour Normal
Breast
HMFG1 (s.c.) 0.01 0.007 -
SM3 (s.c.) 0.007 0.005 - -
SM3 (i.v.) 0.004 0.003 0.005 0.005
In summary we have demonstrated a valuable model for
evaluating the uptake of MoAbs in patients with breast
cancer. Preliminary data suggest no specific uptake of either
HMFG1 or SM3 in patients with breast cancer.
Immunoscintigraphy with 131I-labelled HMFG2 and F (ab')2
HMFG1 in the pre-operative detection of clinical and
subclinical lymph node metastases in breast cancer
A. Athanassiou, D. Pectasides, J. Taylor-Papadimitriou &
A. Epenetos
Anticancer Hospital, Piraeus, Greece and ICRF, London,
UK.
In an attempt preoperatively to detect clinical and subclinical
axillary lymph node metastases in breast cancer, we used
131I-labelled MoAb HMFG2 and HMFG1 F(ab')2. We
studied 10 patients with clinically obvious axillary lymph
node disease (group A), 10 patients with clinically negative
axilla (group B), using MoAb HMFG2, 5 patients with
clinically negative axilla (group C), using MoAb HMFG1
F(ab')2 and 6 patients with clinically positive axillae (group
D) using non-specific MoAb 11.4.1 and 4C4. All patients
had clinical diagnosis of breast cancer. Each patient received
1-1.5mCi as a subcutaneous injection into the webs between
the 2nd and 3rd fingers of both hands. The patients were
scanned at 24-96h post-injection. In group A, 7 patients had
positive scans and 3 negative. The histology and immuno-
peroxidase staining confirmed the presence of tumour in the
lymph nodes in all patients. In group B there were 4 true
positive scans, 4 true negative, 1 false positive and 1 false
negative. Lymph node involvement was histologically con-
firmed in 5 patients. In group C there were 4 true negative
scans. In 1 patient the MoAb stopped in the middle of the
right arm, due to lymphatic obstruction. The histology
confirmed the absence of tumour in the lymph nodes. In
group D, there were 3 true negative scans with MoAb 11.4.1
and 3 true negative scans with MoAb 4C4. The presence of
tumour was histologically confirmed in all patients.
This preliminary study suggests that this approach can
preoperatively detect metastatic tumour in axillary lymph
nodes and be of value in the diagnosis and staging of breast
cancer.
A Japanese phase II study of immunoscintigraphy with 131I
anti CEA and anti CA19-9 monoclonal antibodies
T. Inoue, Y. Sasaki, N. Oriuchi, N. Mitsuhashi,
D. Tsujino, T. Maehara & Y. Suzuki
Gunma University andfive other Institutes, Japan.
The purpose of this study was to evaluate the safety and
clinical usefulness of immunoscintigraphy with 1311 anti
CEA and 1311 anti CA19-9 monoclonal antibody cocktail
(IMACIS 1) which was provided by International CIS
(France). Thirty-six patients with proven cancer in six hospi-
tals were entered in the phase II study. Images were taken
with a gamma camera after injection of IMACIS 1 collecting
300k counts for each view.
Changes of the heart rates, temperature, blood pressure,
respiratory rates and other parameters were obtained. Blood
clearance, urinary excretion and HAMA response were also
investigated.
Positive scintigrams were obtained in 30/36 (83%) patients
and in 39/52 (75%) cancer sites. Blood clearance curves
constituted of two exponential components with mean T1/2 of
7.5 h and 35.4h. Fifty per cent of the injected dose was
excreted in the urine by the 5th day after injection. No
significant changes of the heart rates, temperature, blood
pressure, respiratory rates and clinical laboratory data were
observed. Significant elevation of HAMA titre was not
shown. No adverse reactions were observed in any of the
patients.
On the basis of these results, we plan to commence phase
III clinical trials in Japan.
T cell activation by anti-idiotypic antibody: implications for
vaccine design
Ann D.M. Rees
MRC Tuberculosis and Related Infections Unit, Royal
Postgraduate Medical School, Hammersmith Hospital,
London, UK.
One prediction of Jerne's network hypothesis is that for each
foreign antigenic determinant encountered by the immune
system there must be an idiotype that bears the internal
image. Anti-idiotypic antibodies have possibilities therefore,
as surrogate antigens in vaccine design. In anti-mycobacterial
immunity, however, T-cells mediate protection. Thus our
studies have been directed to the interaction of an anti-
idiotypic antibody (anti-Id TB71) with T-cells reactive to the
myobacterial antigen (38kD) defined by the mouse monoclo-
nal (TB71) used to generate anti-Id TB71. It was found that
38kD specific human T-cell clones also responded to anti-Id
TB71. This suggested that this antibody contained an inter-
nal image in a T-cell stimulatory domain of the 38 kD
molecule. Furthermore, this responsiveness did not depend
on the conformational integrity of the antibody and was
MHC restricted. This suggested that the antibody was
presented to antigen reactive cells by the same mechanisms
as conventional antigen. Anti-Id TB71 may, therefore, stimu-
late an overlapping T-cell repertoire to the 38 kD antigen.
These findings should help in vaccine design.
Treatment of B-cell lymphoma with monoclonal anti-idiotype
(Id) antibodies
R. Miller, Sherri Brown & R. Levy
Stanford University, Stanford, CA and IDEC
Pharmaceuticals Corporation, Mountain View, CA, USA.
Because of their tumour specificity and intrinsic biological
activity, anti-Ids are appealing agents to study for the
treatment of B-cell lymphomas. We have tested the clinical
activity of anti-Ids alone, in combination with alpha inter-
feron (IFN) and radioconjugated with 1311. Fourteen
patients with advanced refractory B-cell lymphoma were
treated with anti-Id alone. One complete response (CR)
lasting 6 years, and 7 partial responses (PR) of 1 month to
greater than 16 months duration were observed. Treatment
with anti-Id in combination with IFN (12 million um 2 threeMONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 311
times a week for 8 weeks) resulted in 1 CR (13 months) and
7 PR (duration 2-15 months). In both studies, evidence for
tumour escape with Ig+, Id- disease was observed. Patients
were treated with up to 12 infusions of anti-Id to total doses
of 8.4g. In most responding patients, tumour regression
continued long after anti-Id disappeared from the serum.
Host anti-mouse Ig response has been avoided in most
patients by increased antibody purity. In order to deal with
Id negative tumour escape, we are using both anti-Id in
combination with chemotherapy and radiolabelled with 1311.
A patient treated with 1311-anti-Id achieved a CR lasting 10
months. We conclude that anti-Id antibodies have reproduc-
ible objective anti-tumour activity in B-cell lymphoma. Stra-
tegies which effectively deal with Id negative lymphoma cells
should improve the extent and duration of these responses.
Lymphoma idiotypes as a therapeutic target
G.T. Stevenson, M.J. Glennie & F.K. Stevenson
Lymphoma Research Unit, Tenovus Laboratory, General
Hospital, Southampton, UK.
Idiotypic determinants of lymphoma cells on Ig molecules of
B-lymphomas or TCR molecules of T are unique differentia-
tion antigens offering a well characterised test-bed for
immunological destruction of neoplasms. The infusion of
anti-idiotypic antibody in patients with lymphoma has
proved a relatively innocuous procedure, but in general has
yielded only partial, short-lived remissions of disease. A
major problem is that xenogeneic antibody is not well fitted
to destroying mammalian cells: complement and cellular
effectors (K-cells and phagocytes) are not efficiently rec-
ruited, and the target cells present some excellent defence
mechanisms such as antigenic modulation. Two broad types
of antibody derivative are under development to improve the
killing of neoplastic targets. One type relies on recruiting
natural effectors, and is exemplified by univalent chimeric
antibody. The other relies on delivering an exogenous effec-
tor such as a drug or toxin and is exemplified by bispecific
anti-Id/anti-saporin F(ab')2 antibody. Both types of deriva-
tive can suppress animal lymphoma to the extent that
tumour escape occurs largely through the emergence of
idiotype-negative mutants. An argument thereby arises for
simultaneously attacking two cell surface antigens.
Lymphoma idiotypes also have attractions as vaccines for
suppressing resurgence of lymphoma after its therapeutic
removal but transplantable animal lymphomas eventually
overcome active anti-idiotypic suppression, sometimes via
modulation, sometimes via mutations.
Replacement of a mucin-associated carbohydrate epitope by
an internal image anti-paratope MAb (Ab2B)
K. Bosslet, J. Friesen, E.J. Kanzy & H.P. Harthus
Behring Research Laboratories, Marburg, W. Germany.
MAb BW 494 binds to a carbohydrate epitope located on a
>200 kDa mucin molecule. The epitope is expressed on
highly differentiated adenocarcinomas of the pancreas, colon
and stomach as well as on mucinous ovarian carcinomas. In
a attempt to use the carbohydrate epitope as a tumour
specific vaccine we tried to mimic this structure producing
(a) MAbs binding to the paratope of MAb BW 494 and (b)
MAbs inducing an Ab3 response with a specificity identical
to that of MAb BW 494.
Syngeneic Bablb/c mice were immunised with the Fab'
fragment of MAb BW 494. Six anti-paratope MAbs which
were able to replace the mucin antigen were established,
purified and coupled via GMBS to KLH. One out of these 6
MAbs, MAb BW 705, was able to induce in syngeneic (Balb/
c mice) and xenogeneic animals (rabbits) an antiserum (Ab3)
binding to pancreatic tumour cell associated mucin and
inhibiting the binding of MAb BW 494 to MAb BW 705.
Attempts are underway, using this internal image anti-
paratope MAb BW 705 (Ab2B), to generate a tumour
specific vaccine for the adjuvant treatment of mucin express-
ing human carcinomas.
Xenosensitisation induced by in vivo injection of murine
monoclonal antibodies
Lucienne Chatenoud, J.C. Saccavini & J.F. Bach
INSERM U25, H6pital Necker, Paris, France and ORIS,
Saclay, France.
Murine monoclonal antibodies (MAb) specific for various
cell membrane antigens are now widely used in clinical
practice as immunosuppressive agents. They are also admi-
nistered in clinical oncology for therapy and diagnosis. One
major side effect of in vivo MAb injection is the immunisa-
tion that almost invariably occurs when MAbs are injected
alone (i.e. in the absence of associated conventional immuno-
suppression). Since 1982 we have studied 75 renal allograft
recipients treated for 14-30 consecutive days with the OKT3
MAb. Human anti-OKT3 antibodies produced (both IgG
and IgM) exhibit a particular specificity since they exclusi-
vely recognise isotopic and idiotypic OKT3 determinants.
Moreover this response was shown to be oligoclonal. Only
the IgG anti-idiotypic component neutralises the MAb thera-
peutic effectiveness. These results were extended to other
anti-T-cell MAbs and a similar response, restricted in terms
of specificity and clonality, was found when analysing 23
rhesus monkeys treated with different anti-CD4 and anti-
CD8 MAbs. More recently 40 patients with ovarian or
colonic tumours that received only one or two 1 mg injec-
tions of labelled F(ab')2 MAb fragments for immunoscinti-
graphy were analysed. Fifteen of them showed significant
antibody titres 10-20 days following even only one MAb
injection. These antibodies were anti-idiotypic thus inhibiting
the binding of injected F(ab')2 MAbs to their targets.
Localisation of monoclonal antibody AUA1 and its F(ab')2
fragments in human tumour xenografts: an autoradiographic
and immunohistochemical study
S. Pervez, A.A. Epenetos, W.J. Mooi, D.J. Evans, G.
Rowlinson, B. Dhokia & T. Krausz
Department of Histopathology and ICRF Group,
Hammersmith Hospital, London, UK.
Monoclonal antibody AUA1 reacts in vitro by staining all
tumour cells mainly on their surface membrane. To investi-
gate the accessibility of these sites by antibody when the
tumour is present as a solid mass in vivo, subcutaneous
xenografts were prepared in nude mice. Mice were injected
i.v. with 1251I-labelled AUA1, 125I AUA1 F(ab')2 or l251_
labelled HMFG2 (a negative control). Animals were killed at
days 1, 3 and 6. Gross and microautoradiography and
immunohistochemistry were performed on frozen and paraf-
fin embedded tissues of tumour and normal organs.
The in vivo injected antibody, in contrast to the in vitro
results, was localised only, on a thin layer of tumour cells
positioned adjacent to vascularised stroma. On small micro-
scopic sized tumour islands the antibody penetration was
complete. Strikingly, most of the radioactivity was mainly on
the cell membrane similar to that seen in vitro. With intact
antibody, similar autoradiographic results were obtained at
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into the tumour at days 1 and 3, but by day 6 the activity
had greatly decreased. Radioactivity in the control organs
was limited to the blood pool with no specific localisation.
Negative control antibody HMFG2 showed no localisation
in the tumour.
These results were not due to differences in antigenic
expression by the tumour cells, as uniform staining was
observed when AUA1 was applied to frozen or paraffin
sections, but more likely reflect the problem of accessibility
of antigenic sites in vivo.
The microdosimetry of alpha emitters in
radioimmunotherapy
D.R. Fisher
Health Physics Department, Pacific Northwest Laboratory,
PO Box 999, Richland, Washington 99352, USA.
Radiation dosimetry is important both for treatment plan-
ning and for evaluating the success of radiation therapy.
Biological response to alpha radiation may be highly vari-
able at a given absorbed dose, depending on the local
distribution of alpha-particle energy. Predicting the effective-
ness of alpha-particle radiation in radioimmunotherapy
depends on adequately characterising the distribution of
energy at the cellular level. Four factors characterise the
microdosimetry of alpha-particle interactions with living
matter: (1) the average (absorbed) dose; (2) the probability
density in specific energy (or distribution of doses to small
targets); (3) the delta function (or fraction of targets comple-
tely missed); and (4) the mean number of hits per target.
Determination of these elements requires careful consider-
ation of the spatial distribution of alpha-emitting sources
with respect to targets, the initial alpha-particle energy, the
number of emissions per source, the relative specific ionis-
ation as a function of track length and the size of the target
(such as the diameter of the cell nucleus). Although precise
correlations have not yet been developed between probability
density in specific energy and the tumour-eradication
effectiveness of alpha-emitting radioimmunoconjugates, such
relationships will become apparent with further experi-
mentation and the careful application of microdosimetric
principles.
Blood clearance of immunotoxins made with different toxin
A-chain and ribosome-inactivating proteins
E.J. Wawrzynczak, A.J. Cumber, R.R. Henry, J. May,
G.D. Parnell, N.R. Worrel & J.A. Forrester
Institute of Cancer Research, Sutton, Surrey, UK.
Immunotoxins were synthesised by attaching ricin A-chain,
abrin A-chain, and two ribosome-inactivating proteins
(RIPs), gelonin and momordin, to a single monoclonal
antibody LICR-LOND-Fib 75. All four immunotoxins were
powerfully and specifically cytotoxic to the human EJ
bladder carcinoma cell line: protein synthesis by EJ cells
growing in tissue culture was inhibited by 50% at immuno-
toxin concentrations ranging between 7 x 1011M and
5 x10-10 M.
The blood clearance of immunotoxins after intravenous
administration to normal rats was measured in the serum
using a solid-phase ELISA specific for each type of toxin A-
chain or RIP. A substantial proportion of Fib 75-ricin A was
lost from the circulation within 2min of injection consistent
with hepatic recognition of oligosaccharide chains present on
ricin A-chain. In contrast, the immunotoxin containing abrin
A-chain, which is not glycosylated, was cleared much less
rapidly so that the serum concentration of Fib 75-abrin A
was 7.5-fold higher than that of Fib 74-ricin A after 24h.
Fib 75-gelonin and Fib 75-mormordin persisted in the blood-
stream at levels intermediate between those of the A-chain
immunotoxins. However, the B-phase half-life on clearance
of the two RIP immunotoxins was similar to that of Fib 75-
ricin A (t112, 8h), contrasting with a longer half-life for
Fib75-abrinA (t112, 15h). This suggests that oligosaccharide
residues present on gelonin and momordin may contribute to
the clearance of immunotoxins containing these RIPs.
Tumour site activation of cytotoxic agent
K.D. Bagshawe, F. Searle, C. Springer, J. Boden,
R. Melton, R. Sherwood & M. Jarman
Cancer Research Campaign Laboratories, Department Of
Medical Oncology, Charing Cross Hospital, London W6
8RF, UK.
The distribution kinetics of antibodies and antibody-toxin
conjugates result in 'areas under the curve' which are less
favourable for the delivery of toxic substances to tumours
than is required for major therapeutic advance. The specifi-
city of antibodies can be used more effectively by delaying
the delivery of a toxin to a time when the tumour/non-
tumour concentration ratios are most favourable and this
requires 'capture' of the toxin or 'activation' of the toxin at
the tumour site. It would also be advantageous if some form
of amplification could be achieved at tumour sites.
These considerations have led to a two-phase approach. In
the first phase a conjugate comprising an antibody fragment
coupled to a non-mammalian enzyme is injected and allowed
to localise at tumour sites. This is followed after an appro-
priate interval by a prodrug characterised by being readily
diffusible at least through extracellular fluids and by being
relatively stable by virtue of a protective group which acts as
substrate for the targeted enzyme. Enzymatic action converts
the product into a highly toxic agent which can diffuse
readily through tumour extracellular fluids and enter cells
but which ideally has a short half-life so that it reaches
normal renewal tissues only in limited amounts.
Experimental data confirm the feasibility of this approach.
Immunotherapy with monoclonal antibodies
G. Schulz, M. Buchler, K.H. Muhrer, R. Klapdor, D.W.
Beelen & K. Bosslet
Research Department, Behringwerke, Marburg, Department
of Surgery, University of Ulm and Giessen, Department of
Internal Medicine, University of Hamburg and Essen, FRG.
MoAbs may induce destruction of tumour or other target
cells by ADCC, CMC or phagocytosis of opsonised circulat-
ing cells. Clinical data demonstrate that these mechanisms
operate in patients. In a phase I/II trial 10 patients with
GvHD grade III after allogeneic BMT have been treated
with a murine MoAb of IgG2b (BI 51.0113) isotype directed
against the human T-cell receptor. Seven out of 8 evaluable
patients showed improvement of symptoms after a 5-day
therapy. In another phase I/II trial, 35 patients with
advanced pancreatic cancer were treated with MoAb 494/32
(BI 51.011) which mediates ADCC and inhibits functional
properties of human pancreatic cancer cells. Total doses up
to 720mg were well tolerated when applied within less than
14 days. Out of 30 evaluable patients, 2 (6.6%) showed a
mixed response, 8 patients (26.7%) had stable disease up to
39 weeks (median=24 weeks), and 20 patients (66.7%) had
progressive disease. Eighteen out of 23 patients developed
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response demonstrated that 3 out of 4 patients produced
anti-idiotypic IgG. Preincubation of effector cells with rh
GM-CSF enhanced ADCC activity in vitro. Patients treated
with rh GM-CSF in a phase I/TI trial demonstrated as rise in
mature neutrophils, eosinophils and monocytes above pre-
treatment levels. Thus a combination of MoAb 494/32 and
GM-CSF result in better tumour response in patients with
pancreatic cancer.
Conversion of xenogeneic monoclonal antibodies to specific
tolerogens
A.H. Sehon
MRC Group for Allergy Research, Department of
Immunology, The University of Manitoba, Winnipeg, MB,
Canada, R3E OW3.
The therapeutic effectiveness of xenogeneic monoclonal anti-
bodies (XIg) or of their conjugates with toxins (XIg-Tx) is
undermined by their inherent immunogenicity. The coupling
of an optimal number of monomethoxypolyethylene glycol
(mPEG) chains (M.wt 3,000-6,000) on to XIg results in
tolerogenic derivatives. The test model in this study consisted
of different inbred strains of mice which received injections
of tolerogenic mPEG conjugates of human monoclonal
(myeloma) immunoglobulins, HIgG(mPEG), and immuno-
geneic doses of heat-aggregated HIgG(ha-HIgG). Admini-
stration of mPEG conjugates of HIgG seven days prior to
immunization with ha-HIgG resulted in a marked suppres-
sion (-90%) of murine IgG, IgM and IgA antibodies to
HIgG. The suppression could be maintained for periods in
excess of 250 days by multiple, alternating injections of
(HIgG)mPEG and Ha-HIgG. The suppression was dose-
dependent and the state of tolerance could be transferred
with spleen cells of immunosuppressed mice to syngeneic
recipients, as well as by freeze/thaw extracts of these cells.
The possible mechanism underlying the immunosuppression
by mPEG conjugates may involve the activation of suppres-
sor T-cells. The conjugates of XIg are expected to be devoid
of antigen binding capacity because of conformational
changes and steric hindrance due to the coupled mPEG
chains. Hence, for therapeutic purposes it is envisaged that it
will be necessary to administer tolerogenic mPEG conjugates
of XIg or XIg-Tx prior to treatment with the corresponding
non-pegylated XIg or XIg-Tx.
Dosimetry of radiolabelled antibodies
T.E. Wheldon
Beatson Oncology Centre, Belvidere Hospital, Glasgow G31
4PG, UK.
Cancer treatment using radiolabelled antibodies is a new
form of therapy. As with conventional radiotherapy, success
will depend on the dose received by critical normal tissues.
Compartmental models may be used to calculate radiation
dose to tumour and various organs. Tumour volume is an
important parameter whose accurate estimation is difficult.
This can be by-passed if we know the uptake of radionuclide
in tumours excised after tracer administration. Estimation of
dose to micrometastases requires the use of mathematical
models which take account of energy dissipation outwith the
tumour. Microdosimetric models are less helpful in assessing
dose to normal tissues. For systemic administration of
radiolabelled antibodies, bone marrow is the dose-limiting
organ. However, regional treatment strategies are developing
for which non-haemopoietic organs may be critical. Also,
bone marrow might be used to obviate haemopoietic
damage. It is likely that doses to non-haemopoietic organs
such as liver will assume increasing importance. It is import-
ant that physical dose calculations be supplemented by
radiobiological models which incorporate dose rate effects.
This is needed to relate the 'tolerance dose' of an organ to
clinical experience using external beam fractionated radio-
therapy. Information obtained from pre-therapeutic trace
studies, should enable prediction of achievable tumour and
normal tissue doses, and the prospective selection of patients
who may benefit from antibody-targeted radiotherapy.
Dose fractionated radioimmunotherapy of lymphoma with
131I Lym-1
Sally J. De Nardo, G.L. De Nardo, D.J. Macey,
S.L. Mills, L.F. O'Grady, J.P. McGahan, E. Hu &
A.L. Epstein
University of California Davis Medical Center, Sacramento,
USA.
Multidose 131I Lym-1, and IgG2a MoAb produced against
Burkitt's lymphoma has been used to treat 16 patients with
aggressive B-cell lymphoma and 2 patients with lymphocytic
leukaemia. Ninety-five doses of 1311 Lym-1 have been given
(1-9 per patient) at 2-6 weeks intervals up to 330mCi.
Each treatment (Rx) consisted of 5-50mg unlabelled Lym-l
preceding 30-60mCi of 1311 Lym-l (3-6mg). Response was
classified as: CR=no detectable disease; PR=tumour regres-
sion >70%; SR=tumour regression >30% <70%;
NR=tumour regression 0-30%.
The patients with leukaemia and nodal disease had PR
after 5 and 2 treatments. Of 16 patients with solid disease, 2
had CR, 5 had PR, and 4 had SR. Of the 5 non-responders,
3 died after one Rx and one developed HAMA after 2 Rx.
Three of 18 patients have developed HAMA. Most patients
have had no toxicity; transient fever, myalgia or hives
occurred in 6 patients, hypotension in one, and a moderate
decrease in platelets occurred in 3 patients. Radiation doses
calculated per mCi ranged from: tumour 2-50, whole body
0.3-0.5 and marrow 0.5-1.2 rads. We conclude that radio-
labelled monoclonal antibodies can be used to treat patients
with B-cell malignancies without significant toxicity, and in
striking contrast to the toxicity associated with chemo-
therapy.
The marked response rate in the face of only modest
toxicity in this study encourages the development of subse-
quent trials.
Intraperitoneal (i.p.) radioimmunotherapy with 131I- and 90Y-
labelled monoclonal antibodies
J.S.W. Stewart, V. Hird and A.A. Epenetos
ICRF Group, Hammersmith Hospital, London, UK.
Pharmacokinetics of i.p. radiolabelled antibodies have been
studied in 35 ovarian cancer patients. Eleven received 1311
and 19 patients 90Y-labelled antibody (5 also receiving i.v.
EDTA). Five patients received 131I-labelled antibody six
weeks after 90Y-labelled antibodies. These patients had deve-
loped antibodies to mouse immunoglobulin (HAMA).
Activity ranged from 100 to 157mCi 1311 and 5 to 20mCi
90Y. Patients had measurements of blood and urine activity.
Lithium fluoride thermoluminescent dosimetry (TLD), was
used to estimate the non-specific radiation to the peritoneum
in 21 patients. Bone marrow dose was estimated using the
MIRD formulation.
In HAMA negative patients, marrow toxicity was the dose
limiting toxicity. Peak blood activity was seen at 40h with
26% and 21% of 1311- and 90Y-labelled antibody in the
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90Y was excreted in the urine. Marrow suppression in
patients receiving 1311 was predicted by our model but was
not predictable in patients receiving 90Y-labelled antibodies.
Additional marrow irradiation from 90Y in bone may
account for this.
HAMA positive patients had less than 5% of the injected
activity in the blood and rapid urinary excretion of 1311. The
urine excretion of 90Y was increased three-fold by intra-
venous EDTA. The radiation dose to the peritoneum was
less than 600cGy, and is unlikely to contribute to tumour
response or local toxicity.
Marrow irradiation is the dose limiting factor with both
1311- and 90Y-labelled antibodies. The dissimilar pharmaco-
kinetics and dosimetry of the isotopes demand different
solution to decrease toxicity and increase efficacy.
Biodistribution of 131I-labelled monoclonal antibodies in
human colon tumours by an ex vivo perfusion model
E. Kraas, E. Lohde, 0. Abri, H. Schlicker, S. Matzku,
H. Kalthoff, W. Schmiegel & I. Chirl
Abtl. u Isotop. Abtl. Berlin, DKFZ Heidelberg, Klin.
Immunologie, Hamburg, West Germany.
The use of monoclonal antibodies for diagnostic and thera-
peutic purposes depends on the uptake and retention of the
antibodies in the target neoplastic tissues. The purpose of the
study was to examine the biodistribution of specific and non-
specific antibodies in resected human colon tumours.
After resection of the colon tumour, the supplying artery
was canulated and perfused with fresh frozen plasma and
Heparin. Continuous control of pressure, flow, temperature,
pH and various metabolic parameters were performed after
administration of 131I-labelled anti-CEA antibody. Highly
differentiated adenocarcinomas of the colon showed a much
higher antibody uptake, than undifferentiated tumours.
Between 3 and 7% of the injected antibody was found in the
tumour tissue. Autoradiography showed inhomogeneous
binding in the tumour tissue. The non-specific antibody-
perfusion showed no tumour binding.
We conclude that the ex vivo perfusion of resected colon
carcinomas can be used to measure the kinetics of binding
and clearance of monoclonal antibodies in tumour tissue by
direct scintigraphy. The cellular biodistribution of the anti-
body can be documented through autoradiography.
Monoclonal antibodies against individual cytokeratins in the
detection of metastatic spread
J. Kovarik, A. Rejthar, L. Lauerova & B. Vojtesek
Department of Immunology, Inst. Medical Research, Brno,
Czechoslovakia.
A panel of 17 monoclonal antibodies recognising epitopes of
keratins 7, 8, 18 and 19 was screened on bone marrow
aspirates and lymph node biopsies of patients with lympho-
proliferative malignancies and non-malignant diseases to
define their reactivity with a non-epithelial structure. The
results revealed that only a limited number of antibodies
exerted constantly no staining of bone marrow elements.
Three antibodies showed a certain degree of positivity con-
fined exclusively to bone marrow cells of patients with
lymphoproliferative ne4splasms, while another 6 antibodies
exhibited non-specific binding in some smears regardless of
their origin. With all antibodies there were positive reactions
with lymph nodes. Staining restricted to keratins 8 and 18
was noted in the extra-follicular reticular cells of all nodes.
Surprisingly, a non-epithelial positive granular staining could
be found with all antibodies in the histiocytic reticular cells
but only in uninvolved lymph nodes of non-Hodgkin's
lymphoma patients. Morphological complementation and
selection of antibodies is necessary in order to avoid false
results when such reagents are used to detect carcinoma
metastatic cells.
A phase I study using iodine-131 labelled OC 125 in the
treatment of epithelial ovarian carcinoma
N.J. Finkler, M.G. Muto, G. Muto, A. Kassis,
C.T. Griffiths, S. Tumeh, V.R. Zurawski Jr. & R.C. Knapp
Brigham and Women's Hospital, 75 Francis Street, Boston,
MA, USA.
The monoclonal antibody (MAb) OC 125 has been shown to
react with approximately 80% of ovarian cancers. Prelimi-
nary investigation using iodine-131 (1311) labelled OC 125
(1-2mCi) given intraperitoneally or intravenously to patients
with either primary or recurrent ovarian cancer indicates
that intraperitoneal administration of antibody conjugate
results in higher concentration of recovered antibody in
tumour.
A phase I clinical trial was carried out utilising 131[-
labelled OC 125 given intraperitoneally to patients with
recurrent epithelial ovarian carcinoma who have failed con-
ventional therapies. To date, 8 patients have been infused
with the radiolabelled antibody. Each patients received a
single injection of an escalating 131I-MAb dose.
All treatments have been well tolerated and without
clinically apparent side effects. No haematopoietic or hepatic
toxicity has been observed. All eight patients are alive. Two
patients evaluable for response have had documented
decreases in tumour burden; one patient had a 50% reduc-
tion in tumour along the small bowel mesentery.
We conclude that 131I-labelled OC 125 may be safely
administered intraperitoneally to patients with recurrent
ovarian cancer and that toxic doses have not yet been met.
Therapeutical application of radiolabelled monoclonal
antibodies: preliminary experiences in 25 patients with solid
tumours
P. Riva & S. Lazzari
Nuclear Medicine Department and Inst. Oncologico
Romagnolo Health Phisic Department, M. Bufalini Hospital,
Cesena, Italy.
Twenty-five patients with advanced neoplastic disease (3
lung, 2 breast, 10 ovarian and 10 colon cancer) were
submitted to radioimmunotherapy following the failure of
chemotherapy and radioimmunotherapy. The antibodies
employed were HMFG1, HMFG2, AUA1, H17E2 (ICRF,
London), BW494/32 (Beheringwerke, FRG), F023C5 and
B72.3 (Sorin Biomedica, Italy). These were chosen on the
basis of immunostaining and immunoscan results and were
labelled with 1311 (mean dose 92mCi). The MoAbs were
administered intravenously (4 patients), intrapleurally (1
patient) and intraperitoneally (20 patients). Thirteen patients
underwent two or more treatments. No early or late adverse
effects were encountered. All patients developed antimouse
antibodies (HAMA) which reduced, during subsequent
courses in the efficacy of the therapy. The calculated dose
delivered to the tumours ranged from 2,000 to 6,300cGy
(mean 3,440cGy). We observed no responses in 9 patients
and partial responses in 4 patients. In 5 patients there was
stabilisation of disease. Significant clinical improvement and
evidence of tumour volume reduction (30-50%) persisting
from 3 to 11 months was achieved in 5 cases. Finally a
complete response lasting from 11 to 15 months was
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Treatment of patients with B-cells malignancies with anti-
CD19 monoclonal antibodies
Anke Honselaar, A. Hekman, J. Sein, Th. Vroom,
S. Israels, R. Somers, W. ten Bokkel, Ph. Rumke &
C. Meief
The Netherlands Cancer Institute, Amsterdam and
Slotervaart Hospital, Amsterdam, The Netherlands.
Five patients with B-cell non-Hodgkin's lymphomas were
treated with the mouse monoclonal antibody CLB-CD19,
subclass IgG2a, directed against the B-cell specific antigen
CD19, not expressed on bone marrow stem cells or plasma
cells. The purpose of this phase I/TI clinical trial was to
determine pharmacokinetics and toxicity. Four patients were
treated with 225mg MoAb intravenously in an escalating
schedule over four consecutive days. One patient received
60mg MoAb twice weekly during a period of 3 weeks.
Treatment was well tolerated. Peak levels of plasma MoAb
ranged from 30 to 70yugm1-1. The plasma half-life of the
MoAb was 22.5 to 60h. The MoAbs could be demonstrated
in the plasma until 10 days after end of treatment. After
each infusion there was a transient decrease in the number of
B-lymphocytes. Remaining B-cells were partially modulated.
Homing of the antibody was found in the bone marrow,
lymph nodes and lymphoma of the skin. Peripheral lympho-
cytes were saturated with MoAbs. Complete saturation was
reached in the bone marrow whilst the cells in lymph nodes
were only partially coated with MoAbs. None of the patients
developed antibodies against the mouse immunoglobulin. No
short or long-term effects were seen in serum immuno-
globulin levels. In one patient a reduction of 43% in
peripheral B-lymphocytes was maintained during 6 weeks
after treatment. Clinically two patients showed a minimal
tumour regression during a period of 3 months.
Isotype variants of CAMPATH-1 antibody: requirements
for effective antibody action in vivo
M.J.S. Dyer, G. Hale, F.G.J. Hayhoe & H. Waldmann
Departments of Haematological Medicine and Immunology,
University of Cambridge, UK.
A series of rat monoclonal antibodies against a non-
modulating antigen (CAMPATH-1) has been produced. All
are lytic with human complement but only the IgG2b
antibody (CAMPATH-IG) is able to elicit antibody-
dependent cellular cytotoxicity with human effector cells.
Twenty patients have received CAMPATH-1G. Normal and
malignant lymphocytes were cleared from the peripheral
blood in all cases. Bone marrow infiltration was cleared in 5
out of 12 assessable cases. Splenomegaly was reduced or
resolved in all 5 cases. Less sensitive were lymph nodes.
CAMPATH-IG is not effective intrathecally. The combi-
nation of non-modulating antigen and correct antibody
isotype allow more effective immune antibody action in man.
Radioimmunolocalisation using a mouse monoclonal antibody
reacting with rat breast and colonic cancer
Louise Baker, C.Y. Yiu, M.J. O'Hare & C.G. Clark
Department of Surgery, University College, London and
Institute of Cancer Research Sutton, Surrey, UK.
In the study of immunotoxin effect on tumour, a syngeneic
animal tumour model is preferable to a xenograft model as
the former should provide a better reflection of immuno-
toxin behaviour when used in the clinical context. However,
few syngeneic models have so far been used for this purpose.
An IgGl mouse monoclonal antibody (JB28.4) has been
raised against a rat colonic cell line RCC2 which was derived
from a transplantable Fischer rat colonic cancer 4047. The
antibody shows a restricted normal tissue distribution in the
rat. It reacts with the cell surface of the transplant and also
with the cell surface of a rat breast cancer cell line MAT B3.
Both tumours can be grown subcutaneously in Fischer rat. A
radiolocalisation study of JB28.4 to these tumours was
performed using 125I-labelled antibody. 1.5-2cm tumour
bearing rats were injected intravenously with 8-10 MBq
(12pg) of labelled antibody and sacrificed at 24, 48 and 72h.
An isotype matches mouse monoclonal LICR-LON M8
which was non-reactive with the tumours was used as a
control. A significant uptake of antibody as measured by the
tumour blood ratios was observed at all time points with the
breast cancer as compared with the control (P<0.001), but
only at 48h (P<0.01) for the colonic tumour.
Expression of human cell surface antigen defined by AuAl
monoclonal antibody in colon cancer and polyps
A. Bamias, D.V. Skarlos, Penelope Paizi-Biza,
E. Samadas, G. Aravantinos, Ekaterini Anagnostaki &
C. Kittas
Agii Anargyri Cancer Hospital and Department of
Pathology, Athens University, Greece.
AuAl monoclonal antibody (ICRF) was derived by immu-
nising BALB/c mice with the colon adenocarcinoma cell line
LoVo. It recognises an epithelial, cell surface protein, coded
by MIC18 gene on chromosome 2. AuAl reacts with a wide
range of epithelial tumours and normal tissues.
In this study, 15 colon cancers of different grading and 15
polyps were stained. Paraffin embedded sections 5,um were
stained with Haematoxylin and Eosin, and immunohisto-
chemically, with AuAl using the indirect immunoperoxidase
method. A synchronous staining of normal colon tissue,
polyps and cancer was performed.
Seventy-eight to 90% of cancer cells showed a very strong
reaction with AuAl monoclonal antibody. This did not
correlate with the grade of the tumour. Polyps showed
weaker reaction with less than 30% of cells being positive.
Micrometastases, not detected by conventional methods,
were revealed by immunohistochemical technique in certain
cases.
Biodistribution of indium-ll1/A5B7 conjugates in a
xenograft model
P. Barnett, R.G. Buckley, P.J. Burke & F. Searle
Cancer Research Campaign Laboratories, Department of
Medical Oncology, Charing Cross Hospital, London W6
8RF, UK.
An anti-CEA antibody A5B7 has been conjugated
with DTPA (using N-hydroxysuccinamide) and DHDE
(N,N' -di(hydroxycarbonylmethyl) -N,N'((2-hydroxy)hydroxy-
carbonylbenzyl)diaminoethane) (using a water soluble
carbodiimide).
Radioimmunoassay and FPLC studies showed that the
conjugation procedure has not impaired the CEA binding
ability of the antibody or induced aggregate formation.
Biodistribution and imaging studies of indium-11 labelled
conjugates have been carried out in nude mice bearing the
human colon carcinoma xenograft LS-174T.
Results showed favourable tumour to tissue ratios for the
DTPA conjugate, enabling tumours to be visualised by
gamma-camera imaging. Tumour to tissue ratios for the
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Induction of expression of glia- and glioma-associated
antigens (GAA) in human glioma cell lines
T. Bilzer, D. Stavrou & W. Wechsler
Department of Neuropathology, University of Dusseldorf
and Institute of Pathology, Hospital Muinchen-Bogenhausen,
FRG
Heterogeneity at the cellular antigen level is the basis of
major problems in neuro-oncology, especially in immuno-
diagnosis and therapy of malignant human gliomas (WHO
grades III and IV). As identified by monoclonal antibodies
(McAbs), anaplastic gliomas are composed of various cell'
subpopulations which may change their antigenicity during
progressive growth. Permanent cell lines and clones of such
gliomas have the tendency to develop into cell populations
which only partly represent the antigenicity of the primary
tumour.
In uncloned cefl lines of two glioblastomas (87HG-28,
87HG-39) and an astrocytoma grade III (86HG-31), respec-
tively, the amount of GAA defined by two McAbs (Muc 2-
39, Muc 2-63) against epitopes on 75 and 96kD glyco-
proteins of the cell surface membrane decreased with increas-
ing number of in vitro passages. In this cells,
immunocytochemistry and Western blots revealed the
presence of GAA within the cytosol. Furthermore, cells were
characterised by an accelerated proliferation rate, an
increased saturation density and a loss of differentiation
markers such as the glial intermediate filament protein
GFAP. After treatment with db-cAMP, GAA-properties,
expression of differentiation markers as well as morpho-
logical and proliferation parameters were widely rearranged,
as illustrated by the reappearance of GAA on the cell
surface, expression of GFAP and extension of cell processes.
Our results suggest approaches to modulate the presence
and responsiveness of antigenic determinants in poorly
differentiated cells of anaplastic human gliomas by the
application of chemicals acting as, or by influence on, their
second messenger systems.
A comparison of antibodies to carcinoembryonic antigen
(CEA) and epithelial membrane antigen (EMA) in human
colorectal cancer
B.R. Davidson, C.Y. Yiu, J. Styles, M. Ormerod,
C.G. Clark & C. Dean
Department of Surgery, University College, London and
Institute of Cancer Research, Sutton, UK.
We compared two high affinity MAbs, one to CEA(C46)
and one to EMA(ICR2) in tissues obtained from 31 patients
with cancer, 14 patients with polyps and 17 with normal
colon. Immunohistochemistry was used and the results classi-




+ve (%) +ve (%)
Carcinoma (n = 18) 15 (83) 18 (100)
Nodal metastases (n=6) 5 (83) 5 (83)
Liver metastases (n =7) 5 (71) 4 (57)
Polyps (n= 14) 1 (7) 11 (79)
Normal colon (n= 17) 2 (12) 12 (71)
The anti-EMA antibody reacts with slightly fewer colonic
cancers than the anti-CEA antibody (83% vs. 100%). The
anti-EMA antibody has fewer reactions, however, with
normal colon (12% vs. 71%) and benign polyps (7% vs.
79%) than the anti-CEA.
Diagnostic and clinical value of immunoscintigraphy with the
F(ab')2 fragment of the monoclonal antibody 225, 28S in
malignant melanoma
Heidi Dazzi, Susan Owens, T. Cerny,
Shirley Mackenzie, Pamela Nuttall & N. Thatcher
Department of Medical Oncology and Reg. Department of
Medical Physics and Bioengineering, Christie Hospital and
Holt Radium Institute, Manchester, UK.
The monoclonal antibody 225, 28S to the high molecular
weight melanoma associated antigen has been tested in
patients with various stages of malignant melanoma. A total
of 70 immunoscintigrams have been performed in 63
patients, using the Tecnemab-I kit (Sorin Biomedica). In
these patients 73 of 113 previously known lesions were
observed (64.4%) and in addition 18 lesions which were
previously unknown were detected. These lesions were later
confirmed by further investigations.
Detailed analysis of the different sites of the metastases
shows that immunoscintigraphy is helpful for detecting
tumour in deep lymph nodes and lower intra-abdominal
masses. In skin and subcutaneous tissue, only larger lesions
were detected (>2cm). Diagnostic information obtained for
pulmonary and gastrointestinal disease is very poor. Non-
specific accumulation was present in the liver, spleen, kidney,
cardiac area, bone marrow, colon and scrotum, as well as in
recent surgical scars and degenerative bone lesions.
We conclude that this procedure is not indicated for
routine screening for metastatic disease in patients with
malignant melanoma. For special problems, such as the
involvement of deep lymph nodes or ocular melanoma, this
technique may provide important information and could,
therefore, be indicated as an additional investigation.
Isolation and biochemical characterisation of a Mr 48,000
glycoprotein recognised by BCD-E8 and BCD-F2 monoclonal
antibodies
Brigitte Grouix, A. Amarouch, R. Jolicoeur & Rosemonde
Mandeville
Immun. Res. Center, Institut Armand-Frappier, Laval-des-
Rapides, Quebec, Canada H7N 4Z3.
Murine monoclonal antibodies BCD-E8 and BCD-F2 were
prepared against the human breast carcinoma cell line BT-
20. A soluble antigen recognised by these antibodies was
obtained by mechanical disruption of the MCF-7 carcinoma
cells. By immunoprecipitation and immunoblotting, we were
able to isolate the antigen recognised by BCD-E8 and BCD-
F2. This antigen was sensitive to periodate oxidation and B-
glycosidase digestion, demonstrating the carbohydrate nature
of the epitope. Moreover, lectin-absorption experiments indi-
cated that BCD-E8 and BCD-F2 recognise oligosaccharide
sequences containing N-acetyl-D-glycosamine residues. We
conclude that both BCD-E8 and BCD-F2 recognise a glyco-
protein with the same molecular weight and the same side
chain.
Increased CA125 elevation in patients after administration of
'311-OC125 caused by human anti-mouse antibodies
H.J. Haisma, K.R. Moseley, R.C. Knapp, E. Boven &
H.M. Pinedo
Departments of Oncology, Dana Farber Cancer Institute,
Boston, USA and Free University Hospital, Amsterdam, the
Netherlands.
CA125 is a valuable tool for monitoring disease in patients
with ovarian cancer. Recently, imaging and therapy studiesMONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 317
have been initiated using antibody OC125. We injected 1311-
labelled OC125 F(ab')2 i.v. or i.p. to localise the tumour
lesions in patients. On analysis of CA125 levels from 17
patients before and at least 1 month after injection of
antibody, 9 patients (54%) had values that had increased to
>5,000 CA125 Uml-1, which could not be explained by
progressive disease. Such high levels were previously
observed in 19 out of 4,500 (0.8%) samples from untreated
patients. In the patients who were injected, CA125 levels
started to rise 4 weeks after injection and remained elevated
for 3 to 24 months. Nine patients had an anti-OC125
antibody response and 7 of them had CA125 levels above
5,000Uml- . Tumour localisation was not impaired by the
antibody response. No correlation could be found between
antibody response, antibody dose, route of administration
and CA125 levels. After preincubation of the sera with
protein A-Sepharose to remove immunoglobulin, CA125
levels dropped precipitously in sera from patients with an
antibody response, but not in sera from patients without an
antibody response. We conclude that human anti-OC125
antibodies interfere with the CA125 assay. This phenomenon
may also occur in patients where other monoclonal anti-
bodies are used both for measuring circulating antigen and
for in vivo studies. We demonstrated that in the presence of
human anti-mouse antibodies, CA125 values can be cor-
rected by removing immunoglobulin from the serum.
Preparation of mouse monoclonal antibodies and their
F(ab')2 fragments for in vivo application
Leena Hakalahti, Riitta Kurkela & Pirkko Vihko
Biocentre and Department of Clinical Chemistry, University
of Oulu, Finland.
Mouse IgGi monoclonal antibodies (MAbs) directed against
human prostatic acid phosphatase were used for radio-
imaging of prostatic cancer metastases in our laboratory. We
have developed two different two-step methods to purify
these MAbs from cell culture media containing 1-5% fetal
calf serum. Methods are based on ion exchange and hydro-
phobic interaction chromatographies. The main contami-
nants, bovine albumin and transferrin are effectively
removed by these methods. Purity analyses made by SDS-
PAGE and sterility and pyrogen tests show that these MAb
meet the requirements given by FDA for MAbs used for in
vivo purposes.
We have also digested IgGI to F(ab')2-fragments using
pepsin and papain digestions. Papain digestion was shown to
be more efficient in F(ab)2-fragmentation for radioimaging
purposes. The yield of F(ab')2-fragments from papain diges-
tion was 50+5% of the theoretical maximum. Both pepsin
and papain digestions gave F(ab')2-fragments with immuno-
reactivity and affinity identical to those of the original IgGI.
Monoclonal antibodies Ki-M3 and Ki-M7 react with renal
cell carcinomas
M.-L. Hansmann, U. Kaiser, I. Papadopoulus &
H.J. Radzun
Pathologisches Institut der Universitat Kiel and
Urologische Universitdts-Klinik, Kiel, FRG.
The monoclonal antibodies Ki-M3 and Ki-M7, which detect
macrophages and monocytic cells, were tested using
immunohistochemistry on a series of benign and malignant
human tumours (n=50). Positive reactivity was detected in
renal cell carcinomas (n=20), a few cases of breast carci-
noma and in one case of prostatic carcinoma. In normal
human kidney, Ki-M3 and Ki-M7 reacted with proximal and
parts of the distal tubules of the Henle limb. Monoclonal
antibodies Ki-M3 and Ki-M7 proved useful in detecting
renal cell carcinomas and in distinguishing these tumours
and their metastases from morphologically similar neoplasm.
Radio silver ("'Ag) separation for labelling monoclonal
antibodies for radioimmunotherapy
D.K. Hazra, V.L. Lahiri, M. Kumari, P. Khanna &
B. Arvind
SN Medical College, Agra, India.
t1tAg by virtue of its 7.45 days T1/2 and beta emission
appeared to be a candidate radionuclide for radioimmuno-
therapy. We describe the preparation of radio silver from
110Pd and the separation of 111Ag from 11 Pd by anion
exchange chromatography.
I°IPd was irradiated for 24h in a neutron flux of
Ix 102ncm-2s-I at the APSARA reactor BARC,
Bombay. Six hours after irradiation the sample was dissolved
in 10ml 10M HCI and applied to a Dowex-I column (8%
cross-linked 100-200 dry mesh, Sigma). The silver is eluted
from this column using 1OM HCI and Pd is retained in the
column. The product is over 99.5% pure and appears
suitable for further processing for radiolabelling. The tech-
nique was earlier standardised using inactive Pd and Ag.
Immunoreactivity of anti-HeLa monoclonal antibody
V.L. Lahiri, D.K. Hazra, B.R. Elhence, K. Singh,
M. Kumari, S. Sarah, B. Arvind & S. Khandelwal
SN Medical College, Agra, India.
A monoclonal antibody, anti-HeLa, was developed against
HeLa cell line (Human Ca Cervix line). The specific reacti-
vity of the MoAb with epitope on the surface of the HeLa
cells was confirmed both by ELISA as well as by indirect
immunoperoxidase staining. Further quantitative reactivity
with HeLa cells was confirmed by RIA. The reactivity of the
anti-HeLa was tested against a panel of malignant tissues by
indirect immunoperoxidase method. Anti-HeLa antibody
showed very strong positivity with squamous cell carcinoma
of cervix but showed only mild positive reaction with
squamous cell carcinoma of buccal mucosa and oesophagus.
Anti-HeLa antibody showed mild reactivity with non-
malignant cervix. Anti-HeLa monoclonal showed reaction
similar to that of anti-keratin antibodies reported by Debus
(1982, 1984) and Ramackers (1983).
Simultaneous dual energy (SDE) radioimmunoscintigraphy
(RIS) in the study of colorectal cancer
L. Jenkins, R. Iorns, M.A. Macleod & R. Leicester
Nuclear Medicine Department, Royal Naval Hospital,
Gosport, Hants P012 2AA, UK.
The aim of this pilot study was to examine the feasibility of
using the SDE technique to ethance the information gath-
ered from radioimmunoscintigraphic examination of patients
with colorectal cancer. It was also hoped that the technique
would lead to the detection of small tumour masses due to
the increased sensitivity of the Tc-labelled nanocolloid. SDE
planar and single photon emission computed tomographic
(SPECT) images were obtained 4-6 days post infusion with
Imacis-l (131I-labelled murine anti-CEA, anti-CA-19.9). The
SDE method requires that an injection of 99Tcm-nanocolloid
is given 24h prior to final imaging.
One patient had a negative scan and was clinically asymp-
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patients with rising levels of CEA and CA-19.9 had positive
SDE scans. Malignancy was confirmed visually (endoscopy)
and histologically. Two patients had primary tumours con-
firmed at operation. The third case was of particular interest
in that Imacis-1 and nonocolloid accumulations were found
at colonoscopy to correspond to polyps (3-5mm). On exter-
nal counting the iodine label was present in one metaplastic
and one dysplastic polyp whilst the 99Tcm-nanocolloid was
present in all three polyps. These initial results are
encouraging.
Pre-targeted immunoscintigraphy in patients with non-small
cell lung cancer (NSCC) using streptavidin conjugated
HMFG1 and indium-11-labelled biotin
H.P. Kalofonos, D.J. Hnatowich, M. Ruschowski,
D. Snook, G.B. Sivolapenko, J.P. Lavender &
A.A. Epenetos
ICRF Oncology Group, Hammersmith Hospital, London,
UK and University of Massachusetts, USA
We describe a new method for in vivo labelling monoclonal
antibodies using streptavidin conjugated monoclonal anti-
body given first (pre-targeted), followed by indium-111-
labelled biotin. We studied four patients with lung cancer
(NSCC) to identify toxicity, localising efficiency, biodistribu-
tion and pharmacokinetics. We administered i.v. unlabelled
HMFG1 antibody conjugated with streptavidin followed 3
days later by indium-111-labelled biotin. Twenty-four hours
after 1111n-biotin administration the uptake by each kidney
was 5.0% and by liver 2.0% of the injected dose. Maximum
tumour concentrations were achieved in 2h but the optimal
time for imaging was at 24h with higher tumour to normal
lung ratios.
Radioactivity in the serum had a T=/2a 2min and T,/2b=
4h. The cumulative urinary excretion of radioactivity over
24h was 78% of the injected dose, of which 70% was
excreted in the first 6h. No toxicity was observed. These
preliminary results indicate an improvement in tumour to
normal tissue ratios, with the exception of kidneys.
Kinetics, quantitative analysis and immunolocalisation using
radiolabelled HMFG1-monoclonal antibody in patients with
breast cancer
H.P. Kalofonos, J.M. Sackier, M.N. Hatzistilianou,
C.B. Wood, J.H. Waxman, P.J. Lavender & A.A. Epenetos
Hammersmith Hospital, London, UK.
HMFG1, IgG and F(ab')2 fragments, radiolabelled with
indium-111, were used to study patients with breast cancer.
Twenty-four patients with primary breast cancer underwent
tumour resection and quantitation of the radioactivity in
tumour versus normal tissue following administration of
specific and non-specific antibodies. The mean tumour
uptake of HMFGI-F(ab)2 fragments at 24h was
5.8 x 10-3% of injected dose per gram of tissue (% IDg'-).
This was higher than the intact antibody 2.6 x 10-3 %
IDg-1 (P<0.05), but at 48 h there was no significant
difference, 5.7 x 10-3 and 7.4 x 10-3% ID g- respectively.
The mean tumour uptake with the specific antibody was
higher than the non-specific antibody of the same subclass,
2.3 x 10-5% ID g-1 (P<0.05). Lymph node metastases,
interestingly, showed higher antibody uptake than the corres-
ponding primary tumours 8.0 x 10-3% ID g - I (P<0.05).
Fifteen patients, were imaged using I11n-F(ab')2
HMFGI-F(ab')2 fragments. We observed positive localisa-
tion in 3 out of 7 with primary lesions, in 4 out of 6 with
bone metastases, in 2 out of 4 with skin infiltration, in 1 out
of 2 with lymph node and in 1 out of 2 with liver metastases.
The optimal time for imaging was 48h. All patients had
significant concentration of "1'In in the liver.
We conclude that HMFGI-F(ab')2 fragments can localise
specifically and faster than the intact IgG in breast cancer.
However, this method needs further improvement prior to
becoming a clinically useful method for staging breast
cancer.
Radiolabelied monoclonal antibodies for localisation and
therapy of brain gliomas
H. Kalofonos, T.R.B. Pawlikowska, D.E. Snook,
P.J. Lavender, C.G. McKenzie, D.G. Thomas &
A.A.Epenetos
Hammersmith Hospital and Institute of Neurology, London,
UK.
Immunoscintigraphy was performed in 21 patients using
iodine-123-labelled monoclonal antibodies against epidermal
growth factor receptor (EGFRI) and placental alkaline
phosphatase (Hl7E2). Ten patients were also imaged using a
non-specific antibody (11.4.1) of the same immunoglobulin
subclass. The specificity of targeting was confirmed by
comparing imaging obtained by specific and non-specific
antibodies. In addition, quantitative evaluation of the anti-
body uptake in tumour versus normal tissue was performed
in 7 patients using the paired antibody technique, following
tumour resection.
Seven patients with recurrent brain glioma (grade III or
IV) who previously showed good localisation of radio-
labelled antibody were treated with 40-140mCi of iodine-
131-labelled antibody delivered to the tumour area intra-
venously or by infusion into the internal carotid artery. Four
patients showed clinical improvement lasting from 6 months
to 2 years. One patient continues in remission 2 years after
therapy but the other 3 who responded initially, relapsed 6-
12 months after therapy and died.
No major toxicity was attributable to antibody guided
irradiation. The patient who received 140mCi developed a
moderate but reversible thrombocytopenia and neutropenia.
These promising but preliminary results should be explored
further in randomised trials.
Enhancement of monoclonal antibody binding after
irradiation of tumour in a xenograft model
H.P. Kalofonos, G. Rowlinson, A.W.J. Stuttle &
A.A. Epenetos
Imperial Cancer Research Fund Oncology Group,
Hammersmith Hospital, London, UK.
Nude mice bearing subcutaneous human colorectal carci-
noma (LoVo), were exposed to single doses of external
irradiation of 40 to 160Gy, followed 24h later by 1111n-
labelled monoclonal antibody. Two antibodies were selected,
AUA1 as specific and HMFG1 as non-specific. Animals
were sacrificed 3 days after antibody administration and
binding of monoclonal antibodies to tumour and normal
tissues was measured. Exposure of the tumours to higher
than 40Gy significantly increased the tumour to blood ratios
with both specific and non-specific antibody (P<0.001).
Specific antibody had approximately a 6-fold in vivo binding
advantage over the non-specific.
The vascular volume in the tumour and normal tissues
was measured using 99Tcm 04 red blood cells. Vascular
permeability was determined by measuring the amount of
1251-labelled non-specific antibody extravasated out of the
tumour vasculature during 1 h. Vascular volume in the
tumour was found to be significantly decreased after expo-MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 319
sure to higher doses than 40Gy (P<0.001). Vascular per-
meability in tumours was higher in all radiation experiments
when compared to non-irradiated values but the increases
were not significant. We conclude that external irradiation
increases specific and non-specific antibody uptake by
tumour possibly due to increased permeability, even though
vascular volume of the tumour is decreased.
The detection of gynaecological malignancies by carcinoma
associated antigen
S.B. Kelley, L.S. Hanna, N.A. Habib, M.J. Hershman,
R.C.N. Williamson & C.B. Wood
Bristol Royal Infirmary and Departments of Surgery and
Obstetrics, Royal Postgraduate Medical School, London,
UK.
Carcinoma associated antigen (CA-50) is a tumour asso-
ciated carbohydrate antigen, defined by the monoclonal
antibody C50, which has been raised against a colorectal
adenocarcinoma cell line. The aim of this study was to assess
whether CA-50 can differentiate patients with gynaecological
malignancies from normal subjects and those with benign
disease. A radioimmunoassay was used for the detection of
CA-50 in the serum of 50 normal subjects, 26 patients with
benign disease and 48 patients with gynaecological malignan-
cies. Serum levels in normal subjects and 21 out of 26
patients (81%) with benign disease were below 17Uml-1,
while 27 out of 48 patients (56%) with carcinoma had levels
above 17Uml-1. The sensitivities for cervical, endometrial
and ovarian carcinomas were 48, 75 and 67% respectively.
In patients with cervical carcinoma, the sensitivity was 46%
for stage I carcinoma, 36% for stage II and 71% for stages
III and IV. Therefore, this test may prove useful in the
diagnosis of patients with gynaecological carcinomas.
Carcinoma associated antigen in the detection of
gastrointestinal carcinomas
S.B. Kelly, N.A. Habib & M.J. Hershman
Department of Surgery, Bristol Royal Infirmary and
Department of Surgery, RPMS, Hammersmith Hospital,
London, UK.
Carcinoma associated antigen (CA-50) is a tumour asso-
ciated carbohydrate antigen, defined by the monoclonal
antibody C50, which has been raised against a colorectal
adenocarcinoma cell line. The aim of this study was to assess
whether CA-50 can differentiate patients with carcinomas,
from normal subjects and those with benign disease. A
radioimmunoassay was used for the detection CA-50 in the
serum of 50 normal subjects, 72 patients with benign disease
and 239 patients with carcinoma of the gastrointestinal tract.
Serum levels in normal subjects and 67 out of 72 patients
(93%) with benign disease were below 17Uml-1, while 157
out of 239 patients (66%) with carcinoma had levels above
17Uml- . The sensitivities for the various carcinomas were
as follows: pancreatic 92% (26 patients), gastric 75% (24),
oesophageal 71% (21), liver 66% (91) and colorectal 51%
(77). In patients with colorectal carcinoma, the sensitivity
was 22% for Dukes' A carcinoma, 29% for Dukes' B, 59%
for Dukes' C and 73% for metastatic disease. The CA-50
levels were elevated in 7 out of 9 patients (78%) who
developed recurrence following curative surgery. In patients
with liver carcinoma, the sensitivity was 70% for cholangio-
carcinoma, 54% for hepatocellular carcinoma and 58% for
metastatic liver disease. Therefore, this test may prove useful
in the diagnosis and monitoring of patients with gastro-
intestinal carcinomas.
Carcinoma associated antigen in the detection of urological
malignancies
S.B. Kelly, N.A. Habib, M.J. Hershman,
R.C.N. Williamson & C.B. Wood
Departments of Surgery, Bristol Royal Infirmary and
Royal Postgraduate Medical School, London, UK.
Carcinoma associated antigen (CA-50) is a tumour asso-
ciated carbohydrate antigen, defined by the monoclonal
antibody C50, which has been raised against a colorectal
adenocarcinoma cell line. The aim of this study was to assess
whether CA-50 can differentiate patients with urological
carcinomas from normal subjects and those with benign
disease. A radioimmunoassay was used for the detection of
CA-50 in the serum of 50 normal subjects, 86 patients with
benign disease and 104 patients with urological carcinomas.
Serum levels in all 50 normal subjects and 83 of 86 patients
(97%) with benign disease were below 17 Uml-1, while 49 of
104 patients (47%) with carcinoma had levels above
17Uml- . The sensitivities for prostatic, bladder and renal
carcinomas were 43%, 62% and 47% respectively. In
patients with prostatic carcinoma, the sensitivities were 0%
for well differentiated carcinomas, 33% for moderately
differentiated carcinomas, 67% for poorly differentiated car-
cinomas and 71% for metastatic disease. The sensitivities for
non-invasive and invasive bladder carcinomas were 42% and
89% respectively. Therefore this test may prove useful in the
diagnosis of patients with urological malignancies.
Cross-linking of mouse monoclonal antibodies into tetra-
molecular antibody complexes using rat monoclonal anti-
isotype antibodies
P.M. Lansdorp & T.E. Thomas
Terry Fox Laboratory, BC Cancer Research Centre,
Vancouver, Canada.
Mouse IgG, monoclonal antibodies can be cross-linked to
form cyclic immune complexes using selected rat monoclonal
antibodies specific for mouse IgG1. Such complexes are
powerful cross-linking reagents as illustrated by their appli-
cations for the labelling of monoclonal antibodies with
enzymes and fluorescent phycobiliproteins and the specific
immunoadsorption of lymphocytes labelled with anti-
hapten x anti-lymphocyte tetramers onto columns containing
hapten coated glass beads. For these applications tetrameric
antibody complexes were prepared with mixtures of two
mouse IgG11 antibodies (e.g. a and b) and bispecific (e.g.
axb) as well as monospecific (axa and bxb) complexes
were obtained. The latter compete with bispecific complexes
for antigenic sites and thereby reduce the efficiency of the
desired bispecific cross-linking. Furthermore, the formation
of tetrameric antibody complexes is currently limited to
mouse antibodies of the IgG1 subclass. In an attempt to
overcome these limitations, rat monoclonal antibodies speci-
fic for mouse IgG2a were raised. Several hybridomas secret-
ing antibodies forming highly stable immune complexes were
isolated. Thus, tetrameric antibody complexes can now be
formed with monoclonal mouse antibodies of both the IgG1
and the IgG2a subclass. The anti-mouse IgG2a hybridomas
are now being used in fusion experiments together with rat
anti-mouse IgG, cell lines with the aim of isolating hybrid
hybridomas producing bispecific antibodies that specifically
cross-link mouse IgG, to mouse IgG2a in a cyclic tetra-
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In vivo experimental targeting of lymphocytes with
1"'In-labelled monoclonal antibodies
I. Loufti, P.M. Chisholm, A.A. Epenetos, J.R. Batchelor &
J.P. Lavender
Royal Postgraduate Medical School, Hammersmith Hospital,
London, UK.
We have investigated the use of an indium-111-labelled Pan
T (MRC OX-19) monoclonal antibody (Mab) in the rat to
establish its usefulness in radiolabelling T-cells for imaging
and therapy purposes. Biodistribution of the unlabelled Mab
after i.v. administration showed early binding to peripheral
blood lymphocytes and late detection of cell-bound antibody
in lymph nodes and spleen. Modulation of the lymphocyte
surface molecule reacting with the antibody in cells obtained
from blood, lymph nodes and spleen was observed and was
marked when high doses of the antibody were used. This
phenomenon was found to be dose dependent. The use of
the In-Ill-labelled Pan T injected i.v. in the rat showed very
early splenic localisation which remained high over 24h,
gradual increase in activity in lymph nodes and steady
background in muscle, lung and liver. Imaging at 20h post-
injection of the In-11 Pan T revealed uptake in the cervical
lymph nodes. This pointed to the usefulness of the technique
for in vivo use having established the optimal conditions in
terms of antibody dose and radioactivity administered.
The clinical evaluation of tumour marker combinations in
the differential diagnosis of benign and malignant liver
disease
Michele Lucarotti, N.A. Habib, S.B. Kelly, M.J. Hershman,
M.J. Cooper, C.B. Wood & R.C.N. Williamson
Department of Surgery, Bristol Royal Infirmary and Royal
Postgraduate Medical School, London, UK.
CEA, CA19-9 and CA50 are tumour associated antigens
defined by monoclonal antibodies. The aim of this study was
to determine whether combined use of CEA, CA19-9 and
CA50 could improve diagnostic accuracy.
An immunoradiometric assay was used for the detection
of CEA and CAl9-9 and the Delfia system for CA50. Serum
was collected from 65 normal subjects, 40 with hepatobiliary
carcinoma (26 primary, 14 secondary and 17 with benign
hepatobiliary disease). The cut-off levels were calculated as
the mean of the control group plus 2 standard deviations.
The results are shown in the table.
Percentage positive
Primary Secondary
Antibody carcinoma carcinoma Benign Normal
CA19-9 46 43 0 9
CA50 50 64 25 11
CEA 20 70 0 8
All three antibodies contributed to improving correct
classification of secondary liver tumours (multivariant discri-
minant analysis P<0.05) but only CA19-9 and CA50 contri-
buted in primary liver tumour diagnosis (multivariant
analysis P<0.05). The diagnostic accuracy vs. benign disease
was 81% for primary and 91% for secondary malignancies.
Combined use of CEA, CA19-9 and CA50 may be useful in
differentiating benign from malignant hepatobiliary disease.
The use of tumour marker combinations in the differential
diagnosis of patients with pancreatic carcinoma
M. Lucarotti, N.A. Habib, S.B. Kelly, M.J. Hershman,
M.J. Cooper, C.B. Wood & R.C.N. Williamson
Departments of Surgery, Bristol Royal Infirmary and Royal
Postgraduate Medical School, London, UK.
CEA, CA19-9 and CA50 are tumour associated antigens
defined by monoclonal antibodies which have been raised
against adenocarcinoma cell lines. No single antibody alone
is specific for the detection of pancreatic malignancy and the
aim of this study was to determine whether the combined
use of CEA, CA19-9 and CA50 would improve diagnostic
accuracy. An immunoradiometric assay was used for the
detection of CEA and CA19-9 and the Delfia system for
DA50. Serum was collected from 65 normal subjects, 16 with
pancreatitis and 28 with pancreatic carcinoma and stored at
-20°C until analysis. The cut-off levels (COL) were calcu-
lated as the mean of the control group plus two standard
deviations. The results are shown in the table.
Percentage positive
Antibody Carcinoma Pancreatitis Normal
CA19-9 85 20 9
CA50 92 19 11
CEA 37 13 8
In order to improve the specificity we used multivariant
discriminant analysis on the combination of antibodies. This
showed that 96% of the malignant group, 13% of the
pancreatitis group and 11% of the normal group were
positive with an overall correct classification of 91% into the
three groups (multivariant discriminant analysis P<0.05).
Combined use of CEA, CA19-9 and CA50 improves diag-
nostic accuracy and may be useful in differentiating benign
from malignant disease.
Immunohistochemical characterisation of a breast cancer
associated antigen using BCD-F2 monoclonal antibody
Rosemonde Mandeville, Salwa Sidrac-Ghali & Lise Giroux
Immunological Research Center, Institut Armand-Frappier,
Laval-des-Rapides, Quebec, Canada H7N 4Z3.
Monoclonal antibodies (MAbs) were produced in mice
immunised by BT-20, a human breast adenocarcinoma cell
line. The screening of these MAbs was performed by both
ELISA and indirect immunofluorescence (IF) techniques
using breast cancer cell lines and fresh frozen tissues.
Hybridomas recognising BT-20 cells but negative with HBL-
100 (putative normal epithelial cell line of breast origin) were
retained for further studies. The biochemical characterisation
of one of these MAbs, BCD-F2, has been determined and
showed that it recognises a breast cancer associated antigen
of Mr 48,000 which appears to be a N-acetyl-D-glycosamine
carbohydrate side chain on a glycoprotein. In the present
study using immunohistochemical techniques, BCD-F2 was
shown to react with 98% (92% strongly and 6% weakly) of
primary breast carcinomas. BCD-F2 also reacted with 82%
(32% strongly and 50% weakly) of carcinomas from extra-
mammary origin and did not recognise sarcomas,
lymphomas or seminomas. These results suggest that BCD-
F2 has potential clinical use in (a) the differential diagnosis
between carcinomas from sarcomas and lymphomas, (b) the
detection of micro-metastases in lymph nodes and (c) the
identification of neoplastic cells in fine needle aspirates and
biopsies.MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 321
Predicting targeting results in ovarian cancer
L. Massuger, R. Verheijen, P. Peelen, L. Poels,
0. Boerman, C. Yedema & P. Kenemans
Departments of Obs. and Gyn., Histology and Urology, St
Radboud Hospital, University of Nijmegen, Free University,
Amsterdam, The Netherlands.
Both accessibility of the tumour associated antigens (TAAs)
and binding of radiolabelled monoclonal (MAbs) to these
TAAs determine the outcome of diagnostic and therapeutic
immunotargeting in ovarian cancer. In order to gain infor-
mation on the amount of antibody-antigen binding we
developed a new method to quantitate the in vitro MAb
binding in tissue sections of 12 epithelial ovarian tumours.
An automated image analysis system, Omnicon FAS II, was
used to quantitate the area of a tumour section stained with
different MAbs using standard immunoperoxidase tech-
niques. In order to assess the tumour associated marker vs.
epithelial marker ratio, tissue sections were stained with
monoclonal OV-TL 12-5 (intermediate filament antibody
specific for epithelial tissue) and the ovarian cancer asso-
ciated MAbs OC125 and OV-TL 3.
In the tumour samples studied, OV-TL 3 tumour cell
binding percentages (OV-TL 3/OV-TL 12-5) ranged from 46
to 137% with a mean of 79.6% whereas OC125 ranged from
4 to 85% with a mean of 50.5%. Therefore OV-TL 3 seems
to be a better candidate for in vivo diagnostic and thera-
peutic targeting in the majority of patients in our study.
This new method of quantitation of antibody-antigen
binding seems to be accurate and reproducible and could be
used to predict clinical targeting results.
Immunoscintigraphy in patients with melanoma
C.L. Mulder, P. Hol, C.A. Hoefnagel, J. Hilkens &
P.F. Bruning
Division of Tumour Biology, The Netherlands Cancer
Institute (Antoni van Leeuwenhoekhuis), Amsterdam, The
Netherlands.
We have performed immunoscintigraphy in patients with
melanoma using 99Tcm-labelled F(ab')2 fragments of MAb
225.28S and 1311-labelled MAb M6 (IgGI). Both MAbs are
directed against a high molecular weight melanoma asso-
ciated antigen.
We have injected MAb 225.28S in 18 patients with
metastatic melanoma. In 8 out of the 18 patients there was
uptake of the labelled MAb by tumour lesions. In organs
with a high non-specific uptake, like liver and spleen, tumour
localisations were seen as cold spots. 1311-labelled M6 was
administered to 4 patients with metastatic melanoma. In one
patient most of the cutaneous and muscular metastases
showed uptake, but pulmonary and abdominal tumour
localisations did not. In another patient there was uptake in
the liver metastases in contrast to a mediastinal mass.
In two other patients no uptake of labelled MAb was
observed in any of the tumour lesions. In one patient there
was a false positive concentration of labelled MAb in the left
femur.
We conclude that immunoscintigraphy with MAb 225.28S
has a low sensitivity and that MAb M6 may prove superior
for imaging.
In vivo scanning with radiolabelied UJ13A in meduliary
carcinoma of thyroid
A. O'Meara, R.J. Fitzgerald, P. Dervan, J. Kingston,
L. Latchford & J. Kemshead
Children's Research Centre, Our Lady's Hospital for Sick
Children, Dublin, Ireland, Department of Pathology, Mater
Misericordiae Hospital, Dublin, Ireland and ICRF, London,
UK.
An 8-year-old girl presented with medullary carcinoma of
thyroid metastatic to cervical nodes on right side of neck.
Following total thyroidectomy and block dissection of right
cervical lymph nodes (Nov. 1986) serum calcitonin remained
elevated at 2,000-2,500 ng 1- 1 (preop. 12,000 ng l- ).
To detect evidence of occult disease, postoperative investi-
gations included pentavalent DMSA (-ve) and MIBG
(-ve). Being a tumour of neuroectodermal origin, tumour
tissue was screened with a panel of monoclonal antibodies to
cells of neuroectodermal origin and demonstrated strong
reactivity to UJ13A. In view of this, she was given an in vivo
dose 3 mCi 1231 UJ13A and this demonstrated slightly
increased uptake in the left side of the neck. Three months
after radioscintigraphy serum calcitonin was 300 ng I.
There is no clinical evidence of disease.
Given the nature of the isotope and the low dose of
radiation administered it is conceivable that the reduction in
serum calcitonin could have been mediated via an ADCC
reaction.
Immunoscintigraphy (IS) with 131Ilabelled HMFG2 and
HMFG1 (Fab')2 vs. abdominal CT scan in the detection of
residual disease in ovarian cancer
D. Pectasides, K. Pateniotis, L. Tzimis, X. Trapali,
P. Natsis, P. Arapantoni, J. Taylor-Papadimitriou,
A. Epenetos, P. Koutsiouba & A. Athanassiou
Anticancer Hospital, Greece and ICRF, London, UK.
i3iI-labelled MoAb HMFG2 and HMFG1 F(ab')2 were
administered intraperitoneally in 15 patients with ovarian
cancer who had completed their chemotherapy. Each patient
received 2-3mCi. Patients were scanned at 24-96h post-
injection. In 3/15 patients IS failed because adhesions pre-
vented diffusion of the MoAb. Of the remaining 12 patients
9 underwent second look laparotomy (SL). Results are





IS was true positive in 8/9 (90%) patients whereas CT in
6/9 (67%) patients. Of the 3 patients not undergoing SL, IS
was positive in all of them whereas clinical examination and
abdominal CT scan were negative. All 3 patients had
subsequent clinical relapse at 3, 4 and 5 months. The IS true
positivity was 92% (11/12 patients) whereas CT was 50%
(6/12%).
We conclude that IS with intraperitoneal administration of
13II-labelled MoAb can accurately detect the presence of
residual disease in ovarian cancer. In this pilot study it
proved more sensitive than abdominal CT scan.322 MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY
Localisation of biotinylated monoclonal antibodies in nude
mice bearing subcutaneous and intraperitoneal human tumour
xenografts
S. Pervez, G. Paganelli, A.A. Epenetos, W.J. Mooi,
D.J. Evans & T. Krausz
Department of Histopathology and ICRF Oncology
Laboratory, Hammersmith Hospital, London, UK.
To assess the precise distribution of in vivo injected mouse
monoclonal antibodies in nude mice on histological sections,
one can use radiolabelled antibodies for autoradiography, or
employ immunohistochemical methods. Autoradiography,
though very useful, is time consuming and does not provide
a precise picture of the cellular localisation of the antibody.
With conventional immunohistochemical techniques there is
also possible interaction of the anti-mouse antibody with the
host tissue antigens.
To overcome this problem we have biotinylated our
primary antibodies (AUA1 and CEA) and injected each
separately intra-peritoneally into nude mice bearing simulta-
neous subcutaneous and intraperitoneal xenografts of the
human tumour 'LOVO' (a cell line established from an
adenocarcinoma of the colon). Twenty-four hours after
injection, the animals were sacrificed, tumours and control
organs were studied. Antibody was demonstrated on frozen
sections by incubating sections with avidin biotin peroxidase
complex.
We compared the in vivo penetration and distribution of
these antibodies on intraperitoneal and subcutaneous
tumours as well as control organs. The antibody penetration
was restricted to the thin layer of tumour cells adjacent to
the vascular stroma in large solid subcutaneous and intra-
peritoneal tumours, whereas in very small intraperitoneal
tumours, antibody penetration was complete. These findings
were similar to our autoradiographic results.
This study demonstrates that employing biotinylated anti-
bodies for in vivo localisation studies provides superior
resolution of antibody binding for morphological assessment
compared to autoradiography. Localisation of a biotin label
is more precise and will permit ultrastructural studies.
Evaluation of serum CA 125 levels in the monitoring of
response to chemotherapy in epithelial ovarian carcinoma
(EOC)
M. Quaranta, M. Coviello, G. Micelli, A. Casamassima,
I. Abbate, M. Correale & V. Lorusso
Institute of Oncology, Bari, Italy.
Recently, a monoclonal antibody-based immunoassay (EIA)
for CA 125 antigen has been used to monitor the treatment
of EOC. Serum CA 125 levels were evaluated in 60 patients,
mean age 56 (30-69 years), with ovarian cancer. CA 125
reference limit was 35Um-1, as proposed by Bast. Serial
CA 125 measurements were assessable in 23 patients under-
going chemotherapy. Rising, falling and unchanged levels
correlated with disease in 21 of 23 cases (95%). Ten out of
eleven patients who showed objective response to chemo-
therapy had a decrease in antigen levels. Two out of three
patients with stable disease had unchanged levels, and pro-
gression (n=9) was always associated with rising levels.
Mean value of decreased levels was 65% (range 30-95%).
Antigen levels
Disease status Decreased Unchanged Increased
Complete response 3 - -
Partial response 7 1 -
Stable disease 1 2 -
Progression - - 9
These data suggest that CA 125 may aid in early identi-
fication of non-responders. However, a normal CA 125 level
does not exclude the presence of disease.
Intravenous EDTA to reduce bone uptake of 90Y following
90Y-labelled antibody administration
Gail Rowlinson, D. Snook, S. Stewart & A.A. Epenetos
ICRF Oncology Group, Hammersmith Hospital, London,
UK.
Marrow toxicity due to bone uptake of 90Y is the dose-
limiting factor in radioimmunotherapy using 90Y-labelled
monoclonal antibodies. Using a human tumour xenograft
model, we have investigated the efficacy of EDTA (ethytene-
diaminetetraacetic acid) in removing free 90Y from the
circulation, but not from the antibody.
Nude mice with intraperitoneal tumours of the human
colon carcinoma, LOVO, were injected intraperitoneally with
90Y-labelled AUAI antibody. Half of the animals received
20mg EDTA intravenously 2h after antibody administ-
ration, and then every 24h until dissection. Percentage of
injected dose g-1 and tumour to normal tissue ratios were
compared in the two groups of mice.
Two days after antibody administration the tumour/bone
ratios (mean+s.d.) in untreated mice was 3.6+ 1.1, compared
with 7.8 + 1.6 in EDTA-treated mice (P<0.05). Of the other
tumour/normal tissue ratios, only kidney showed any signifi-
cant difference (control 2.0+0.5 vs. treated 4.0+1.0, P<0.05).
The percentage of injected dose g-1 of tissue in blood,
tumour and all normal organs except bone and kidney was
not significantly different, indicating that the 90Y was not
removed from the bound and circulating antibody.
Excretion of 90Y in the urine of EDTA-treated mice was
2.7 times higher than in controls at 18 and 24h after
antibody injection. There was no significant difference at
48h by which time most of the circulating free 90Y had been
chelated by the EDTA and excreted.
These studies indicate that EDTA may be used to reduce
90Y toxicity, without adversely affecting the antibody-guided
radiation dose to tumour.
Combination of immunoscintigraphy and CA125 serum levels
in ovarian cancer
Ch. Schatten, N. Pateiskey, P. Sevelda, K. Czerwenka,
M. Barrada, K. Philipp & J. Burchell
First Department of Obstetrics and Gynaecology, Vienna,
Austria and ICRF, London, UK.
Forty-three patients with a history of ovarian cancer were
investigated prior to second-look surgery using immuno-
scintigraphy (IS) and determinations of CA125 serum levels.
While IS provide information concerning the localisation of
tumour sites, CA125 serum levels >35IU served as an
indicator for recurrent disease. For IS an IgG1 mouse
monoclonal antibody HMFG2, raised against human-milk-
fat-globule and expressed on the cell surface membrane of
ovarian cancer cells, was employed after labelling with 1231.
In 27 out of 30 cases IS proved to be true positive and in 9
out of 13 cases true negative. In 29 patients CA125 serum
levels were also assessed. The combination of both methods
showed superior results than each method alone. In this case
the value of sensitivity could be raised to 0.94, specificity to
1.00, accuracy 0.96, positive prediction 1.00 and negative
prediction 0.88, respectively.MONOCLONAL ANTIBODIES IN CLINICAL ONCOLOGY 323
Induction of tolerance to xenogeneic immunoglobulins
G.B. Sivolapenko, R.J. Edwards, M. Kanariou,
N.S. Courtenay-Luck, A.A. Epenetos & M.A. Ritter
Hammersmith Hospital, London, UK and Aghia Sophia
Hospital, Athens, Greece.
Humoral responses against passively administered immuno-
globulins had always been a problem for all kinds of
serotherapy. We attempted to reduce this response by care-
fully deaggregating (Superose 6 or 12, on FPLC) immuno-
globulins.
When deaggregated, polyclonal human IgG was injected
i.p. into Balb/c mice, there was no significant reduction in
the primary anti-human IgG response, whereas with CBA
and C57BL/6 there was a reduced response. A second
injection boosted the humoral response of the Balb/c,
whereas CBA and C57BL/6 responded only partially. When
Cyclosporin A was administered to Balb/c, we obtained a
reduction in responses. When rats (Lou/c) and rabbits (1/
2 lop) were immunised with a deaggregated mouse mono-
clonal antibody, we did not obtain any difference in their
anti-mouse IgG response compared to controls. In a group
of 10 patients with cancer we administered deaggregated
1311-labelled mouse monoclonal antibody and in another
group of 10 patients 90Y-labelled antibody, which was
aggregated during the radiolabelling procedure. We obtained
no difference in the humoral responses against mouse IgG
between those 2 groups.
Our data, therefore, show that deaggregation of xeno-
geneic IgG does not prevent the host's humoral anti-Ig
responses.
Imaging thrombus with radiolabelled Fab' fragments of a
monoclonal antibody to platelets
A.W.J. Stuttle, C.J. O'Donnell, N. Virji, A.M. Peters,
R.C. Harrison, G.J.P. Murphy & J.P. Lavender
Hammersmith Hospital, London and Amersham
International, UK.
A simple rapid method, not requiring blood cell separation,
is required for platelet labelling in the diagnosis of DVT. We
have previously reported our preliminary clinical findings
with an i.lv. monoclonal antibody (P256), raised in mice
labelled with "'In and specific for primate platelet glyco-
protein Ilb/Illa complex. The effect of P256 and its Fab;
fragments on in vitro platelet function have been assessed by
measuring platelet aggregation in whole blood, platelet rich
plasma and gel filtered platelets. The F(ab')2 fragment
caused consistently less aggregation than the whole antibody,
whilst the monovalent Fab' fragment had no effect. The
monovalent Fab' fragment was therefore investigated for its
ability to image thrombus in vivo. After labelling with "'In,
via the bifunctional chelate DTPA, the P256 Fab retained
reactivity and specificity for primate platelets. Thrombus was
induced in M.fascicularis by i.v. injection of iron micro-
spheres and localised with an externally applied magnetic
field. Thrombus was confirmed by venography and imaged
with "'In-P256 Fab'. The venogram and scintigram were
both positive at 1 and 48 h after thrombus induction. These
initial studies show good correlation between imaging with
P256 Fab' fragment and venography for detection of DVT.
Biodistribution of "'In OC 125 monoclonal antibody
(MABG) in nude mice bearing intraperitoneal human ovarian
carcinoma
Ph. Thedrez, M. Kremer, C. Curtet, C. Sai, D. Guerreau,
J.C. Saccavini & J.F. Chatal
INSERM U 211, Nantes and Comp. ORIS Ind., Grif sure
Yvette, France.
Intact MAB OC 125 with high specificity for ovarian
carcinoma was labelled with "1'In or 1311 and injected
intraperitoneally or intravenously into nude mice bearing
human ovarian carcinoma NIH:OVCAR-3 in order to com-
pare biodistribution according to the radiolabel used and
route of administration. Mice were sacrificed at: 2h, 24h,
96h and 7 days. Results are expressed in % of injected dose
per gram and in tumour-to-tumour ratios.
Tumour uptake 24h after i.p. injection was higher with
"1In OC 125 (28+7.44) than with a non-specific immuno-
globulin (II1In NS) (6.86+1.35). The kinetics of uptake also
differed, showing a plateau followed by a drop at day 7 with
IIIIn OC 125 and a decrease beginning at 24h with IIIIn
NS. Tumour-to-normal-tissue ratios ranged between 29+ 1.10
and 4+0.84 with IIIIn OC 125 and between 9.48+6.82 and
0.89+0.29 with "'In NS. After intravenous injection, the
maximum uptake in tumour with "'In OC 125 was only
14.6+2.7 at 96h, with a lower tumour-to-normal tissue ratio.
The i.p. injection of 1311-OC 125 showed lower uptake in
tumour (13.5+4.2, 4.8+3.2, 3.5+1.3 and 0.3+0.1 at the
different time intervals) but with tumour-to-tissue ratios
equal to those obtained with "'In OC 125. Biodistribution
of i.p.-injected radiolabelled colloids was also performed and
showed maximum tumour uptake at 96h (20.2+5.3) but with
elevated non-specific uptake in liver (31.0 +6.2) and spleen
(55.2+ 14.1). These results indicate high and selective tumour
uptake of IIIIn OC 125 after i.p. injection and suggest an
i.p. radioimmunotherapy could be carried out by replacing
IIIIn with 90Y.
Monoclonal antibodies against mesenchymal antigens of the
human mammary gland
A.A. Verstraeten, Ph.C. Hageman & J.H. Daams
Division of Tumourbiology, Antoni van Leeuwenhoekhuis,
Plesmanlaan 121, Amsterdam, The Netherlands.
Interactions between epithelial and stromal components are
known to be involved in epithelial carcinogenesis of the
mammary gland. Tenascin, an extracellular matrix (ecm)
protein with a hexabrachion (Mackie et al., P.N.A.S. 84,
4621, 1987.
In search of markers for ecm-components of human
mammary tumours monoclonal antibodies (moabs) were
raised against a stroma-enriched preparation of a human
mammary carcinoma specimen and selected, by immuno-
histochemistry on frozen sections of normal mammary
glands and mammary tumours, for their reactivity with
tumour stroma. Two moabs, T3C8 and T2H5, fulfilled the
criteria and were further characterised. The reaction pattern
of T3C8 closely resembles the pattern obtained with rabbit-
anti-tenascin-antiserum (kindly provided by Dr. E.J.
Mackie), i.e. a clearly positive staining of tumour-stroma,
especially on the border tumour/stroma, and also around
normal pre-existing ducts and alveoli and in the wall of
blood vessels. The reaction pattern of T2H5 was very similar
to T3C8; however, no reaction was seen around normal
ducts and alveoli. The stroma of fibroadenomas was positive
with both antibodies.
As yet no biochemical data are available on the bio-
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moabs, nor whether they are related to tenascin or other
ecm-components. The distribution pattern of these moabs,
however, demonstrates its usefulness in studying the role of
ecm in tumour formation.
Immunoscintigraphy of colorectal cancer using indium
labelled monoclonal antibody 77.1
C.Y. Yiu, Louise Baker, B.R. Davidson, K~-Roberts,
Gill Clarke, R. McCready, J. Westwood, P.B. Boulos &
C.G. Clark
University College, London, Royal Marsden Hospital and
Institute of Cancer Research, London, UK.
77.1 (IgG2a), a monoclonal antibody raised against bladder
cancer was found to react with colorectal cancer on
immunocytochemistry. Xenograft localisation studies con-
firmed localisation of 77.1 to target tumour. An immuno-
scintigraphy study was performed using "'In-labelled 77.1.
Fourteen patients with 15 tumours took part in the study.
Two of patients had recurrent disease. "'In-labelled anti-
body was injected intravenously and scanning was performed
at 3-5 days after injection. Immunocytochemistry was per-
formed on resected tumours. Positive scans were obtained
for 10 tumours (64%) in 10 patients. Surgical specimen was
not available for staining for one patient who had a positive
scan. All patients with positive scans had positive immuno-
cytochemistry. The tumours from three patients with nega-
tive scans stained positively with 77.1. One patient whose
tumour stained negatively with 77.1 also had a negative scan.
Analysis of specimens resected six days following antibody
administration revealed a mean tumour to normal colon
ratio of 1.93 (range 1.0-3.26) and a mean tumour to blood
ratio of 3.55 (range 1.6-5.07). These results are similar to
those obtained with other antibodies used in immunoscinti-
graphy of colorectal cancer and suggest that further evalu-
ation of this antibody is indicated.
Immunoscintigraphy of colorectal cancer with an antibody
reactive with epithelial membrane antigen (EMA)
C.Y. Yiu, L. Baker, B.R. Davidson, M. Ward,
K...Roberts, G. Clarke, C. Ward, J. Westwood,
P.A: Boulos & C.G. Clark
Departments of Surgery and Nuclear Medicine, University
College, Royal Marsden Hospital, St George's Hospital and
Institute of Cancer Research, London, UK.
Immunoperoxidase staining of LICR-LON M8, a mouse
monoclonal antibody reactive with epithelial membrane
antigen (EMA) showed reaction with sections of colorectal
cancer. I I IIn-labelled M8 has already been used in the
immunoscintigraphy of breast cancer. These findings
prompted an immunoscintigraphic study of colorectal cancer
patients with "'In-labelled M8. Eighteen patients took part
in the study. Histological sections were available from 16
patients for immunocytochemistry. "'In-labelled M8 was
injected intravenously and scanning took place at 3-5 days.
Positive scans were obtained from 13 patients (65%). All
tumours with positive scans had positive staining with M8.
The tumours from 2 patients with negative scans also had
negative staining with M8. Three patients had positive
immunocytochemistry but negative scans. The surgical speci-
men available from one patient at day 4 showed a tumour
blood ratio of 3.5. Eleven patients had samples taken of
tumour and normal tissues on day 6. The ratio of antibody
uptake of tumour to normal colon was 2.56+1.27
(mean+s.d.) and the ratio of tumour to blood activity was
11.0+6.2 (mean+s.d.). These results suggest that there is
specific uptake of "'In-labelled M8 by tumours.
Immunohistochemistry with monoclonal antibodies to a
sialomucin in adenolymphomas of the parotid gland: a novel
method for epitope recognition
St. Zotter, Ph. Hageman, A. Lossnitzer, Jvd. Tweel,
J. Hilkens, W. Mooi & J. Hilgers
Institute of Pathol. Anatomy, Dresden, DDR, Departments
of Tumour Biology, Pathology, NKI and Department of
Obs. & Gyn., VU, Amsterdam, The Netherlands.
Fourteen monoclonal antibodies (MoAbs) to the epithelial
membrane antigen (EMA) complex on a sialomucin molecule
were studied for their immunohistochemical reactivity with
serial sections of fourteen formalin-fixed and paraffin-
embedded adenolymphomas of the parotid gland. Two types
of reactivity were observed, suggesting different cellular
deposition of the corresponding epitopes. Most antibodies
reacted with the luminal membrane of an upper layer of
epithelial tumour cells (type A reaction). The other reaction
(type B) was observed with the membrane of basal epithelial
cells. The antibo.dies could be ranked according to their
tendency to show type A and/or type B reactions. MoAb Cal
was the only one with a pure type A reaction. A strong
preference of type A reactivity (with traces of type B
reactions) was observed for the antibodies HMFG-2, M8,
E29 and NCRC-11. Several antibodies gave good type B
reactions in addition to strong A type reactivity (MoAbs
126E7, 115G2, 115D8, 140C1, F36/22, 139H2). MoAb DF3
showed equally strong reactions with both cell types. A
clear-cut preference of the reactions with basal cells was seen
with the antibodies HMFG-1 and 115F5. The subclassi-
fication of the antibodies does fit epitope mapping, by
conventional blocking studies, reported in the literature.